1
|
Josserand V, Lavaud J, Keramidas M, Collet C, Traboulsi W, Hoffmann P, Feige JJ, Benharouga M, Coll JL, Alfaidy N. RGD-Based Fluorescence to Assess Placental Angiogenesis. Methods Mol Biol 2024; 2728:131-136. [PMID: 38019397 DOI: 10.1007/978-1-0716-3495-0_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2023]
Abstract
Normal fetal growth and placental development depend on active angiogenesis occurring at the fetomaternal interface throughout pregnancy. Nevertheless, reliable in vivo methods to assess placental angiogenesis are still missing. Here, we describe a quantitative and noninvasive in vivo method to specifically measure placental neovascularization in the gravid mouse. This method uses a technique based on the measurement of a fluorescent molecule Angiostamp700 that targets the alpha v beta 3 (αvβ3) integrin, a protein that is highly expressed by endothelial cells during the neovascularization and by trophoblast cells during invasion of the maternal decidua. Due to this noninvasive method, quantification of the fetomaternal angiogenic activity and information regarding the outcome of pregnancy are now possible.
Collapse
Affiliation(s)
- Veronique Josserand
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Jonathan Lavaud
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Michelle Keramidas
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Constance Collet
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Wael Traboulsi
- Laboratory for Immuno-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA
| | - Pascale Hoffmann
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
- Centre Hospitalo-Universitaire Grenoble Alpes, Service Obstétrique, CS 10217, Grenoble Cedex 9, France
- Université Grenoble Alpes, Grenoble, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Centre Hospitalo-Universitaire Grenoble Alpes, Service Obstétrique, CS 10217, Grenoble Cedex 9, France
- Université Grenoble Alpes, Grenoble, France
| | - Mohamed Benharouga
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France
- University Grenoble-Alpes, Grenoble, France
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France
| | - Jean-Luc Coll
- Institute for Advanced Biosciences, INSERM-UGA U1209, CNRS UMR 5309, La Tronche, France
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Inserm U1292, Biosanté, Grenoble, France.
- University Grenoble-Alpes, Grenoble, France.
- Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Biosciences and Biotechnology Institute of Grenoble, Grenoble, France.
- Centre Hospitalo-Universitaire Grenoble Alpes, Service Obstétrique, CS 10217, Grenoble Cedex 9, France.
- Université Grenoble Alpes, Grenoble, France.
| |
Collapse
|
2
|
Ferreira RR, de Souza EM, Vilar-Pereira G, Degrave WMS, Abreu RDS, Meuser-Batista M, Ferreira NVC, Ledbeter S, Barker RH, Bailly S, Feige JJ, Lannes-Vieira J, de Araújo-Jorge TC, Waghabi MC. In Chagas disease, transforming growth factor beta neutralization reduces Trypanosoma cruzi infection and improves cardiac performance. Front Cell Infect Microbiol 2022; 12:1017040. [PMID: 36530434 PMCID: PMC9748701 DOI: 10.3389/fcimb.2022.1017040] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 11/08/2022] [Indexed: 12/05/2022] Open
Abstract
Chronic Chagasic cardiomyopathy (CCC), a progressive inflammatory and fibrosing disease, is the most prominent clinical form of Chagas disease, a neglected tropical disease caused by Trypanosoma cruzi infection. During CCC, the parasite remains inside the cardiac cells, leading to tissue damage, involving extensive inflammatory response and irregular fibrosis. Among the fibrogenic factors is transforming growth factor-β (TGF-β), a key cytokine controlling extracellular matrix synthesis and degradation. TGF-β is involved in CCC onset and progression, with increased serum levels and activation of its signaling pathways in the cardiac tissue, which crucially contributes to fibrosis. Inhibition of the TGF-β signaling pathway attenuates T. cruzi infection and prevents cardiac damage in an experimental model of acute Chagas disease. The aim of this study was to investigate the effect of TGF-β neutralization on T. cruzi infection in both in vitro and in vivo pre-clinical models, using the 1D11 monoclonal antibody. To this end, primary cultures of cardiac cells were infected with T. cruzi trypomastigote forms and treated with 1D11. For in vivo studies, 1D11 was administered in different schemes for acute and chronic phase models (Swiss mice infected with 104 parasites from the Y strain and C57BL/6 mice infected with 102 parasites from the Colombian strain, respectively). Here we show that the addition of 1D11 to cardiac cells greatly reduces cardiomyocyte invasion by T. cruzi and the number of parasites per infected cell. In both acute and chronic experimental models, T. cruzi infection altered the electrical conduction, decreasing the heart rate, increasing the PR interval and the P wave duration. The treatment with 1D11 reduced cardiac fibrosis and reversed electrical abnormalities improving cardiac performance. Taken together, these data further support the major role of the TGF-β signaling pathways in T. cruzi-infection and their biological consequences on parasite/host interactions. The therapeutic effects of the 1D11 antibody are promising and suggest a new possibility to treat cardiac fibrosis in the chronic phase of Chagas' heart disease by TGF-β neutralization.
Collapse
Affiliation(s)
- Roberto Rodrigues Ferreira
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil,Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil,*Correspondence: Roberto Rodrigues Ferreira, ; Mariana Caldas Waghabi,
| | - Elen Mello de Souza
- Laboratório de Virologia Molecular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Glaucia Vilar-Pereira
- Laboratório de Biologia das Interações, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Wim M. S. Degrave
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Rayane da Silva Abreu
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Marcelo Meuser-Batista
- Departamento de Anatomia Patológica e Citopatologia, Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Nilma Valéria Caldeira Ferreira
- Departamento de Anatomia Patológica e Citopatologia, Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Steve Ledbeter
- Tissue Protection and Repair, Sanofi-Genzyme R&D Center, Framingham, MA, United States
| | - Robert H. Barker
- Tissue Protection and Repair, Sanofi-Genzyme R&D Center, Framingham, MA, United States
| | - Sabine Bailly
- Laboratory BioSanté, Université Grenoble Alpes, INSERM, CEA, Grenoble, France
| | - Jean-Jacques Feige
- Laboratory BioSanté, Université Grenoble Alpes, INSERM, CEA, Grenoble, France
| | - Joseli Lannes-Vieira
- Laboratório de Biologia das Interações, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Tania C. de Araújo-Jorge
- Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
| | - Mariana Caldas Waghabi
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil,*Correspondence: Roberto Rodrigues Ferreira, ; Mariana Caldas Waghabi,
| |
Collapse
|
3
|
Ferreira RR, Waghabi MC, Bailly S, Feige JJ, Hasslocher-Moreno AM, Saraiva RM, Araujo-Jorge TC. The Search for Biomarkers and Treatments in Chagas Disease: Insights From TGF-Beta Studies and Immunogenetics. Front Cell Infect Microbiol 2022; 11:767576. [PMID: 35186778 PMCID: PMC8847772 DOI: 10.3389/fcimb.2021.767576] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Accepted: 12/03/2021] [Indexed: 11/23/2022] Open
Abstract
The anti-inflammatory cytokine transforming growth factor beta (TGF-β) plays an important role in Chagas disease (CD), a potentially life-threatening illness caused by Trypanosoma cruzi. In this review we revisited clinical studies in CD patients combined with in vitro and in vivo experiments, presenting three main sections: an overview of epidemiological, economic, and clinical aspects of CD and the need for new biomarkers and treatment; a brief panorama of TGF-β roles and its intracellular signaling pathways, and an update of what is known about TGF-β and Chagas disease. In in vitro assays, TGF-β increases during T. cruzi infection and modulates heart cells invasion by the parasite fostering its intracellular parasite cycle. TGF-β modulates host immune response and inflammation, increases heart fibrosis, stimulates remodeling, and slows heart conduction via gap junction modulation. TGF-β signaling inhibitors reverts these effects opening a promising therapeutic approach in pre-clinical studies. CD patients with higher TGF-β1 serum level show a worse clinical outcome, implicating a predictive value of serum TGF-β as a surrogate biomarker of clinical relevance. Moreover, pre-clinical studies in chronic T. cruzi infected mice proved that inhibition of TGF-β pathway improved several cardiac electric parameters, reversed the loss of connexin-43 enriched intercellular plaques, reduced fibrosis of the cardiac tissue, restored GATA-6 and Tbox-5 transcription, supporting cardiac recovery. Finally, TGF-β polymorphisms indicate that CD immunogenetics is at the base of this phenomenon. We searched in a Brazilian population five single-nucleotide polymorphisms (-800 G>A rs1800468, -509 C>T rs1800469, +10 T>C rs1800470, +25 G>C rs1800471, and +263 C>T rs1800472), showing that CD patients frequently express the TGF-β1 gene genotypes CT and TT at position -509, as compared to noninfected persons; similar results were observed with genotypes TC and CC at codon +10 of the TGF-β1 gene, leading to the conclusion that 509 C>T and +10 T>C TGF-β1 polymorphisms are associated with Chagas disease susceptibility. Studies in genetically different populations susceptible to CD will help to gather new insights and encourage the use of TGF-β as a CD biomarker.
Collapse
Affiliation(s)
- Roberto Rodrigues Ferreira
- Laboratory of Innovations in Therapies, Education and Bioproducts, Oswaldo Cruz Institute (LITEB-IOC/Fiocruz), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
- Laboratory of Functional Genomics and Bioinformatics, Oswaldo Cruz Institute (LAGFB-IOC/Fiocruz), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
- *Correspondence: Tania C. Araujo-Jorge, ; Roberto Rodrigues Ferreira,
| | - Mariana Caldas Waghabi
- Laboratory of Functional Genomics and Bioinformatics, Oswaldo Cruz Institute (LAGFB-IOC/Fiocruz), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
| | - Sabine Bailly
- Laboratory Biology of Cancer and Infection, Université Grenoble Alpes, Inserm, Commissariat à l’Energie Atomique, Grenoble, France
| | - Jean-Jacques Feige
- Laboratory Biology of Cancer and Infection, Université Grenoble Alpes, Inserm, Commissariat à l’Energie Atomique, Grenoble, France
| | - Alejandro M. Hasslocher-Moreno
- Clinical Research Laboratory of Chagas Disease, Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
| | - Roberto M. Saraiva
- Clinical Research Laboratory of Chagas Disease, Evandro Chagas National Institute of Infectious Disease, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
| | - Tania C. Araujo-Jorge
- Laboratory of Innovations in Therapies, Education and Bioproducts, Oswaldo Cruz Institute (LITEB-IOC/Fiocruz), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
- *Correspondence: Tania C. Araujo-Jorge, ; Roberto Rodrigues Ferreira,
| |
Collapse
|
4
|
Waghabi MC, Ferreira RR, Abreu RDS, Degrave W, de Souza EM, Bailly S, Feige JJ, de Araújo-Jorge TC. Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease. Mem Inst Oswaldo Cruz 2022; 117:e210395. [PMID: 35239842 PMCID: PMC8896758 DOI: 10.1590/0074-02760210395] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 12/20/2021] [Indexed: 12/05/2022] Open
Abstract
Transforming growth factor beta (TGF-β) is deeply involved on the pathogenesis of Chagas disease. Our group has been investigating the participation of this pleiotropic cytokine in different aspects of Chagas disease over the last 20 years. Important observations have been made, such as: (i) the ability of Trypanosoma cruzi in activating latent TGF-β; (ii) the potential involvement of TGF-β pathway on T. cruzi invasion of host cells; (iii) association of TGF-β with parasite intracellular replication; (iv) cardiac fibrosis development and maintenance; (v) disruption of Connexin-43 plaque structures and (vi) inflammation and immune response. In this perspective article we intend to discuss the advances of the potential use of new therapies targeting TGF-β to treat the cardiac alterations of Chagas disease-affected patients.
Collapse
Affiliation(s)
| | | | | | | | | | - Sabine Bailly
- Institut National de la Santé et de la Recherche Médicale, France
| | | | | |
Collapse
|
5
|
Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2020; 15:4. [PMID: 31910860 PMCID: PMC6945546 DOI: 10.1186/s13023-019-1281-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2019] [Accepted: 12/16/2019] [Indexed: 12/11/2022] Open
Abstract
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000–8000 individuals worldwide. This rare disease is characterized by various vascular defects including epistaxis, blood vessel dilations (telangiectasia) and arteriovenous malformations (AVM) in several organs. About 90% of the cases are associated with heterozygous mutations of ACVRL1 or ENG genes, that respectively encode a bone morphogenetic protein receptor (activin receptor-like kinase 1, ALK1) and a co-receptor named endoglin. Less frequent mutations found in the remaining 10% of patients also affect the gene SMAD4 which is part of the transcriptional complex directly activated by this pathway. Presently, the therapeutic treatments for HHT are intended to reduce the symptoms of the disease. However, recent progress has been made using drugs that target VEGF (vascular endothelial growth factor) and the angiogenic pathway with the use of bevacizumab (anti-VEGF antibody). Furthermore, several exciting high-throughput screenings and preclinical studies have identified new molecular targets directly related to the signaling pathways affected in the disease. These include FKBP12, PI3-kinase and angiopoietin-2. This review aims at reporting these recent developments that should soon allow a better care of HHT patients.
Collapse
Affiliation(s)
- Florian Robert
- Univ. Grenoble Alpes, Inserm, CEA, Laboratory Biology of Cancer and Infection, F-38000, Grenoble, France
| | - Agnès Desroches-Castan
- Univ. Grenoble Alpes, Inserm, CEA, Laboratory Biology of Cancer and Infection, F-38000, Grenoble, France
| | - Sabine Bailly
- Univ. Grenoble Alpes, Inserm, CEA, Laboratory Biology of Cancer and Infection, F-38000, Grenoble, France
| | - Sophie Dupuis-Girod
- Univ. Grenoble Alpes, Inserm, CEA, Laboratory Biology of Cancer and Infection, F-38000, Grenoble, France.,Hospices Civils de Lyon, Service de Génétique, Hôpital Femme-Mère-Enfants, F-69677, Bron, France.,Centre National de Référence pour la Maladie de Rendu-Osler, F-69677, Bron, France
| | - Jean-Jacques Feige
- Univ. Grenoble Alpes, Inserm, CEA, Laboratory Biology of Cancer and Infection, F-38000, Grenoble, France.
| |
Collapse
|
6
|
Desroches-Castan A, Tillet E, Ricard N, Ouarné M, Mallet C, Belmudes L, Couté Y, Boillot O, Scoazec JY, Bailly S, Feige JJ. Bone Morphogenetic Protein 9 Is a Paracrine Factor Controlling Liver Sinusoidal Endothelial Cell Fenestration and Protecting Against Hepatic Fibrosis. Hepatology 2019; 70:1392-1408. [PMID: 30964206 DOI: 10.1002/hep.30655] [Citation(s) in RCA: 69] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Accepted: 04/04/2019] [Indexed: 12/15/2022]
Abstract
Bone morphogenetic protein 9 (BMP9) is a circulating factor produced by hepatic stellate cells that plays a critical role in vascular quiescence through its endothelial receptor activin receptor-like kinase 1 (ALK1). Mutations in the gene encoding ALK1 cause hereditary hemorrhagic telangiectasia type 2, a rare genetic disease presenting hepatic vessel malformations. Variations of both the circulating levels and the hepatic mRNA levels of BMP9 have been recently associated with various forms of hepatic fibrosis. However, the molecular mechanism that links BMP9 with liver diseases is still unknown. Here, we report that Bmp9 gene deletion in 129/Ola mice triggers hepatic perisinusoidal fibrosis that was detectable from 15 weeks of age. An inflammatory response appeared within the same time frame as fibrosis, whereas sinusoidal vessel dilation developed later on. Proteomic and mRNA analyses of primary liver sinusoidal endothelial cells (LSECs) both revealed that the expression of the LSEC-specifying transcription factor GATA-binding protein 4 was strongly reduced in Bmp9 gene knockout (Bmp9-KO) mice as compared with wild-type mice. LSECs from Bmp9-KO mice also lost the expression of several terminal differentiation markers (Lyve1, Stab1, Stab2, Ehd3, Cd209b, eNos, Maf, Plvap). They gained CD34 expression and deposited a basal lamina, indicating that they were capillarized. Another main characteristic of differentiated LSECs is the presence of permeable fenestrae. LSECs from Bmp9-KO mice had a significantly reduced number of fenestrae. This was already observable in 2-week-old pups. Moreover, we could show that addition of BMP9 to primary cultures of LSECs prevented the loss of their fenestrae and maintained the expression levels of Gata4 and Plvap. Conclusion: Taken together, our observations show that BMP9 is a key paracrine regulator of liver homeostasis, controlling LSEC fenestration and protecting against perivascular hepatic fibrosis.
Collapse
Affiliation(s)
| | - Emmanuelle Tillet
- BCI Laboratory, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - Nicolas Ricard
- BCI Laboratory, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - Marie Ouarné
- BCI Laboratory, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - Christine Mallet
- BCI Laboratory, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - Lucid Belmudes
- BGE Laboratory, Université Grenoble Alpes, CEA, Inserm, Grenoble, France
| | - Yohann Couté
- BGE Laboratory, Université Grenoble Alpes, CEA, Inserm, Grenoble, France
| | - Olivier Boillot
- Liver Transplant Unit, Edouard Herriot Hospital, Hospices Civils de Lyon, Lyon, France
| | - Jean-Yves Scoazec
- Department of Pathology, Gustave Roussy Cancer Campus, Villejuif, France
| | - Sabine Bailly
- BCI Laboratory, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| | - Jean-Jacques Feige
- BCI Laboratory, Université Grenoble Alpes, Inserm, CEA, Grenoble, France
| |
Collapse
|
7
|
Ferreira RR, Abreu RDS, Vilar-Pereira G, Degrave W, Meuser-Batista M, Ferreira NVC, da Cruz Moreira O, da Silva Gomes NL, Mello de Souza E, Ramos IP, Bailly S, Feige JJ, Lannes-Vieira J, de Araújo-Jorge TC, Waghabi MC. TGF-β inhibitor therapy decreases fibrosis and stimulates cardiac improvement in a pre-clinical study of chronic Chagas' heart disease. PLoS Negl Trop Dis 2019; 13:e0007602. [PMID: 31365537 PMCID: PMC6690554 DOI: 10.1371/journal.pntd.0007602] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 08/12/2019] [Accepted: 07/03/2019] [Indexed: 01/11/2023] Open
Abstract
TGF-β involvement in Chagas disease cardiomyopathy has been clearly demonstrated. The TGF-β signaling pathway is activated in the cardiac tissue of chronic phase patients and is associated with an increase in extracellular matrix protein expression. The aim of this study was to investigate the effect of GW788388, a selective inhibitor of TβR1/ALK5, on cardiac function in an experimental model of chronic Chagas' heart disease. To this end, C57BL/6 mice were infected with Trypanosoma cruzi (102 parasites from the Colombian strain) and treated orally with 3mg/kg GW788388 starting at 120 days post-infection (dpi), when 100% of the infected mice show cardiac damage, and following three distinct treatment schedules: i) single dose; ii) one dose per week; or iii) three doses per week during 30 days. The treatment with GW788388 improved several cardiac parameters: reduced the prolonged PR and QTc intervals, increased heart rate, and reversed sinus arrhythmia, and atrial and atrioventricular conduction disorders. At 180 dpi, 30 days after treatment interruption, the GW3x-treated group remained in a better cardiac functional condition. Further, GW788388 treatment reversed the loss of connexin-43 enriched intercellular plaques and reduced fibrosis of the cardiac tissue. Inhibition of the TGF-β signaling pathway reduced TGF-β/pSmad2/3, increased MMP-9 and Sca-1, reduced TIMP-1/TIMP-2/TIMP-4, and partially restored GATA-6 and Tbox-5 transcription, supporting cardiac recovery. Moreover, GW788388 administration did not modify cardiac parasite load during the infection but reduced the migration of CD3+ cells to the heart tissue. Altogether, our data suggested that the single dose schedule was not as effective as the others and treatment three times per week during 30 days seems to be the most effective strategy. The therapeutic effects of GW788388 are promising and suggest a new possibility to treat cardiac fibrosis in the chronic phase of Chagas' heart disease by TGF-β inhibitors.
Collapse
Affiliation(s)
- Roberto Rodrigues Ferreira
- Laboratório de Genômica Funcional e Bioinformática—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
| | - Rayane da Silva Abreu
- Laboratório de Genômica Funcional e Bioinformática—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
| | - Glaucia Vilar-Pereira
- Laboratório de Biologia das Interações—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
| | - Wim Degrave
- Laboratório de Genômica Funcional e Bioinformática—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
| | - Marcelo Meuser-Batista
- Laboratório de Inovações em Terapias, Ensino e Bioprodutos—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
- Departamento de Anatomia Patológica e Citopatologia, Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil
| | - Nilma Valéria Caldeira Ferreira
- Departamento de Anatomia Patológica e Citopatologia, Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brasil
| | - Otacílio da Cruz Moreira
- Laboratório de Biologia Molecular e Doenças Endêmicas, Instituto Oswaldo Cruz (FIOCRUZ/RJ), Rio de Janeiro, Brazil
| | - Natália Lins da Silva Gomes
- Laboratório de Biologia Molecular e Doenças Endêmicas, Instituto Oswaldo Cruz (FIOCRUZ/RJ), Rio de Janeiro, Brazil
| | - Elen Mello de Souza
- Laboratório de Virologia Molecular—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
| | - Isalira P. Ramos
- UFRJ, Centro Nacional de Biologia Estrutural e Bioimagem, Rio de Janeiro, RJ, Brazil
| | - Sabine Bailly
- Université Grenoble-Alpes, Inserm, CEA, Biology of Cancer and Infection Laboratory, Grenoble, France
| | - Jean-Jacques Feige
- Université Grenoble-Alpes, Inserm, CEA, Biology of Cancer and Infection Laboratory, Grenoble, France
| | - Joseli Lannes-Vieira
- Laboratório de Biologia das Interações—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
| | - Tania C. de Araújo-Jorge
- Laboratório de Inovações em Terapias, Ensino e Bioprodutos—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
| | - Mariana Caldas Waghabi
- Laboratório de Genômica Funcional e Bioinformática—Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro RJ, Brasil
- * E-mail:
| |
Collapse
|
8
|
Guignabert C, Tu L, Feige JJ, Humbert M, Bailly S. Response by Guignabert et al to Letter Regarding Article, “Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension”. Circ Res 2019; 124:e82-e83. [DOI: 10.1161/circresaha.119.315053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Christophe Guignabert
- INSERM UMR_S 999, Université Paris-Sud, Université Paris-Saclay, AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Ly Tu
- INSERM UMR_S 999, Université Paris-Sud, Université Paris-Saclay, AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Jean-Jacques Feige
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France
| | - Marc Humbert
- INSERM UMR_S 999, Université Paris-Sud, Université Paris-Saclay, AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Sabine Bailly
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France
| |
Collapse
|
9
|
Tu L, Desroches-Castan A, Mallet C, Guyon L, Cumont A, Phan C, Robert F, Thuillet R, Bordenave J, Sekine A, Huertas A, Ritvos O, Savale L, Feige JJ, Humbert M, Bailly S, Guignabert C. Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circ Res 2019; 124:846-855. [DOI: 10.1161/circresaha.118.313356] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Ly Tu
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
| | - Agnès Desroches-Castan
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France (A.D.-C., C.M., L.G., F.R., J.-J.F., S.B.)
| | - Christine Mallet
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France (A.D.-C., C.M., L.G., F.R., J.-J.F., S.B.)
| | - Laurent Guyon
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France (A.D.-C., C.M., L.G., F.R., J.-J.F., S.B.)
| | - Amélie Cumont
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
| | - Carole Phan
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
| | - Florian Robert
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France (A.D.-C., C.M., L.G., F.R., J.-J.F., S.B.)
| | - Raphaël Thuillet
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
| | - Jennifer Bordenave
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
| | - Ayumi Sekine
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France (A.S., A.H., L.S., M.H.)
| | - Alice Huertas
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France (A.S., A.H., L.S., M.H.)
| | - Olli Ritvos
- Department of Bacteriology and Immunology and Department of Physiology, Faculty of Medicine, University of Helsinki, Finland (O.R.)
| | - Laurent Savale
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France (A.S., A.H., L.S., M.H.)
| | - Jean-Jacques Feige
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France (A.D.-C., C.M., L.G., F.R., J.-J.F., S.B.)
| | - Marc Humbert
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- AP-HP, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, France (A.S., A.H., L.S., M.H.)
| | - Sabine Bailly
- Université Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l’Infection, Grenoble, France (A.D.-C., C.M., L.G., F.R., J.-J.F., S.B.)
| | - Christophe Guignabert
- From the INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
- Faculté de Médecine, Université Paris-Sud and Université Paris-Saclay, Kremlin-Bicêtre, France (L.T., A.C., C.P., R.T., J.B., A.S., A.H., L.S., M.H., C.G.)
| |
Collapse
|
10
|
Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, Pineau R, Guérit S, Maitre M, Dedieu S, Jeanne A, Bailly S, Feige JJ, Miletic H, Rossi M, Bello L, Falciani F, Bjerkvig R, Bikfalvi A. Deciphering the complex role of thrombospondin-1 in glioblastoma development. Nat Commun 2019; 10:1146. [PMID: 30850588 PMCID: PMC6408502 DOI: 10.1038/s41467-019-08480-y] [Citation(s) in RCA: 117] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 01/09/2019] [Indexed: 12/17/2022] Open
Abstract
We undertook a systematic study focused on the matricellular protein Thrombospondin-1 (THBS1) to uncover molecular mechanisms underlying the role of THBS1 in glioblastoma (GBM) development. THBS1 was found to be increased with glioma grades. Mechanistically, we show that the TGFβ canonical pathway transcriptionally regulates THBS1, through SMAD3 binding to the THBS1 gene promoter. THBS1 silencing inhibits tumour cell invasion and growth, alone and in combination with anti-angiogenic therapy. Specific inhibition of the THBS1/CD47 interaction using an antagonist peptide decreases cell invasion. This is confirmed by CD47 knock-down experiments. RNA sequencing of patient-derived xenograft tissue from laser capture micro-dissected peripheral and central tumour areas demonstrates that THBS1 is one of the gene with the highest connectivity at the tumour borders. All in all, these data show that TGFβ1 induces THBS1 expression via Smad3 which contributes to the invasive behaviour during GBM expansion. Furthermore, tumour cell-bound CD47 is implicated in this process. Thrombospondin-1 (THSB1) is a component of the ECM with a role in regulating cancer development and tumour vasculature. Here, the authors show that TGF-beta-induced THBS1 expression contributes to the invasive behaviour of GBM cells and promotes resistance to antiangiogenic therapy partially through interaction with CD47.
Collapse
Affiliation(s)
- Thomas Daubon
- INSERM U1029, Institut Nationale de la Santé et de la Recherche Médicale, 33615, Pessac, France. .,University Bordeaux, 33615, Pessac, France. .,KG Jebsen Brain Tumor Research Center, University of Bergen, 5020, Bergen, Norway. .,Norlux Beuro-Oncology, Department of Biomedicine, University of Bergen, 5020, Bergen, Norway.
| | - Céline Léon
- INSERM U1029, Institut Nationale de la Santé et de la Recherche Médicale, 33615, Pessac, France.,University Bordeaux, 33615, Pessac, France
| | - Kim Clarke
- Computational Biology Facility, University of Liverpool, Liverpool, L69 7ZB, UK
| | - Laetitia Andrique
- INSERM U1029, Institut Nationale de la Santé et de la Recherche Médicale, 33615, Pessac, France.,University Bordeaux, 33615, Pessac, France
| | - Laura Salabert
- INSERM U1029, Institut Nationale de la Santé et de la Recherche Médicale, 33615, Pessac, France.,University Bordeaux, 33615, Pessac, France
| | - Elodie Darbo
- UMR1218 ACTION, Bioinformatic Center CBiB, University of Bordeaux, 33076, Bordeaux, France
| | - Raphael Pineau
- Animal Facility, University Bordeaux, 33615, Pessac, France
| | - Sylvaine Guérit
- INSERM U1029, Institut Nationale de la Santé et de la Recherche Médicale, 33615, Pessac, France.,University Bordeaux, 33615, Pessac, France
| | - Marlène Maitre
- INSERM U1215, Neurocenter Magendie, Pathophysiology of Addiction Group, 33076, Bordeaux, France
| | | | - Albin Jeanne
- CNRS UMR 7369, MEDyC, 51687, Reims, France.,SATT Nord, 59800, Lille, France
| | | | | | - Hrvoje Miletic
- KG Jebsen Brain Tumor Research Center, University of Bergen, 5020, Bergen, Norway.,Department of Pathology, Haukeland University Hospital, 5020, Bergen, Norway
| | - Marco Rossi
- Neurosurgical Oncology Unit, Department of Oncology and Hemato-Oncology, Humanitas Research Hospital, Universita Degli Studi di Milano, 20089, Rozzano, Milan, Italy
| | - Lorenzo Bello
- Neurosurgical Oncology Unit, Department of Oncology and Hemato-Oncology, Humanitas Research Hospital, Universita Degli Studi di Milano, 20089, Rozzano, Milan, Italy
| | - Francesco Falciani
- Computational Biology Facility, University of Liverpool, Liverpool, L69 7ZB, UK
| | - Rolf Bjerkvig
- KG Jebsen Brain Tumor Research Center, University of Bergen, 5020, Bergen, Norway.,Norlux Beuro-Oncology, Department of Biomedicine, University of Bergen, 5020, Bergen, Norway.,Oncology Department, Luxembourg Institute of Health, 84, Val Fleuri, 1526, Luxembourg
| | - Andréas Bikfalvi
- INSERM U1029, Institut Nationale de la Santé et de la Recherche Médicale, 33615, Pessac, France. .,University Bordeaux, 33615, Pessac, France.
| |
Collapse
|
11
|
Subileau M, Merdzhanova G, Ciais D, Collin-Faure V, Feige JJ, Bailly S, Vittet D. Bone Morphogenetic Protein 9 Regulates Early Lymphatic-Specified Endothelial Cell Expansion during Mouse Embryonic Stem Cell Differentiation. Stem Cell Reports 2018; 12:98-111. [PMID: 30595547 PMCID: PMC6335586 DOI: 10.1016/j.stemcr.2018.11.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 11/30/2018] [Accepted: 11/30/2018] [Indexed: 01/06/2023] Open
Abstract
Exogenous cues involved in the regulation of the initial steps of lymphatic endothelial development remain largely unknown. We have used an in vitro model based on the co-culture of vascular precursors derived from mouse embryonic stem cell (ESC) differentiation and OP9 stromal cells to examine the first steps of lymphatic specification and expansion. We found that bone morphogenetic protein 9 (BMP9) induced a dose-dependent biphasic effect on ESC-derived vascular precursors. At low concentrations, below 1 ng/mL, BMP9 expands the LYVE-1-positive lymphatic progeny and activates the calcineurin phosphatase/NFATc1 signaling pathway. In contrast, higher BMP9 concentrations preferentially enhance the formation of LYVE-1-negative endothelial cells. This effect results from an OP9 stromal cell-mediated VEGF-A secretion. RNA-silencing experiments indicate specific involvement of ALK1 and ALK2 receptors in these different BMP9 responses. BMP9 at low concentrations may be a useful tool to generate lymphatic endothelial cells from stem cells for cell-replacement strategies. Low doses of BMP9 raise lymph-vasculogenesis during ESC differentiation NFATc1 signaling operates in BMP9-induced lymphatic endothelial cell expansion High doses of BMP9 increase LYVE-1-negative endothelial cell formation A specific differential involvement of ALK1 and ALK2 mediates the BMP9 effects
Collapse
Affiliation(s)
- Mariela Subileau
- Univ. Grenoble Alpes, Inserm, CEA, BIG-BCI, Grenoble 38000, France
| | | | - Delphine Ciais
- Univ. Grenoble Alpes, Inserm, CEA, BIG-BCI, Grenoble 38000, France
| | | | | | - Sabine Bailly
- Univ. Grenoble Alpes, Inserm, CEA, BIG-BCI, Grenoble 38000, France
| | - Daniel Vittet
- Univ. Grenoble Alpes, Inserm, CEA, BIG-BCI, Grenoble 38000, France.
| |
Collapse
|
12
|
Benfateh M, Cissoko S, Boufettal H, Feige JJ, Samouh N, Aboussaouira T, Benharouga M, Alfaidy N. Risk factors and poor prognostic factors of preeclampsia in Ibn Rochd University Hospital of Casablanca: about 401 preeclamptic cases. Pan Afr Med J 2018; 31:225. [PMID: 31447983 PMCID: PMC6691300 DOI: 10.11604/pamj.2018.31.225.14401] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Accepted: 03/14/2018] [Indexed: 11/11/2022] Open
Abstract
Preeclampsia is a gestational pathology that complicates 2 to 8% of pregnancies and is one of the major causes of maternal and fetal morbidity and mortality worldwide. The aim of this work was to study the epidemiological profile of preeclampsia in Casablanca and to identify risk factors as well as factors of poor maternal and fetal prognosis. 401 preeclamptic cases were collected in the gynecology-obstetrics "C" Service of Lalla Meryem Maternity of Ibn Rochd University Hospital of Casablanca (2010-2011) were included in this study and a statistical analysis with the SPSS software version (16.0) was performed. We used the Chi-2 test to analyze qualitative variables and Student's test and ANOVA (analysis of variance) for quantitative variables. The incidence of preeclampsia was (7.1%). The epidemiological profile was that of a primipara (57.6%), average age 30 years and (66.8%) of pregnancies were not followed. Multiparity was a factor of poor maternal prognosis (p = 0.007). The low gestational age and no prenatal care were factors of maternal as well as fetal prognosis. Risk factors frequently found in our patients were obesity (15.21%) and chronic hypertension (5.73%) as vascular-renal history; abortion (16.46%) and perinatal death (5.24%) as obstetric history. Preeclampsia is a common obstetric pathology in our context. Better prenatal care and early diagnosis could reduce its incidence.
Collapse
Affiliation(s)
- Meriem Benfateh
- Unité de Culture Cellulaire, CED, Faculté de Médecine et de Pharmacie, Hassan II University of Casablanca, Maroc
| | - Souadou Cissoko
- Unité de Culture Cellulaire, CED, Faculté de Médecine et de Pharmacie, Hassan II University of Casablanca, Maroc
| | - Houssine Boufettal
- Service C de Gynécologie, CHU Ibn Rochd, Faculté de Médecine et de Pharmacie, Hassan II University of Casablanca, Maroc
| | - Jean-Jacques Feige
- Institut de Biosciences et Biotechnologie du CEA de Grenoble, Unité U1036 INSERM, Grenoble, France
| | - Naima Samouh
- Service C de Gynécologie, CHU Ibn Rochd, Faculté de Médecine et de Pharmacie, Hassan II University of Casablanca, Maroc
| | - Touria Aboussaouira
- Unité de Culture Cellulaire, CED, Faculté de Médecine et de Pharmacie, Hassan II University of Casablanca, Maroc
| | - Mohamed Benharouga
- Commissariat à l'Energie Atomique (CEA), DSV-iRTSV, 17 rue des Martyrs, France-Université Grenoble-Alpes, Centre National de la Recherche Scientifique, UMR 5249, 38054 Grenoble Cedex 9, France
| | - Nadia Alfaidy
- Institut de Biosciences et Biotechnologie du CEA de Grenoble, Unité U1036 INSERM, Grenoble, France
| |
Collapse
|
13
|
Tillet E, Ouarné M, Desroches-Castan A, Mallet C, Subileau M, Didier R, Lioutsko A, Belthier G, Feige JJ, Bailly S. A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma. J Biol Chem 2018; 293:10963-10974. [PMID: 29789425 DOI: 10.1074/jbc.ra118.002968] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2018] [Revised: 05/04/2018] [Indexed: 11/06/2022] Open
Abstract
Bone morphogenetic protein 9 (BMP9) and BMP10 are the two high-affinity ligands for the endothelial receptor activin receptor-like kinase 1 (ALK1) and are key regulators of vascular remodeling. They are both present in the blood, but their respective biological activities are still a matter of debate. The aim of the present work was to characterize their circulating forms to better understand how their activities are regulated in vivo First, by cotransfecting BMP9 and BMP10, we found that both can form a disulfide-bonded heterodimer in vitro and that this heterodimer is functional on endothelial cells via ALK1. Next, we developed an ELISA that could specifically recognize the BMP9-BMP10 heterodimer and which indicated its presence in both human and mouse plasma. In addition to using available Bmp9-KO mice, we generated a conditional Bmp10-KO mouse strain. The plasma from Bmp10-KO mice, similarly to that of Bmp9-KO mice, completely lacked the ability to activate ALK1-transfected 3T3 cells or phospho-Smad1-5 on endothelial cells, indicating that the circulating BMP activity is mostly due to the BMP9-BMP10 heterodimeric form. This result was confirmed in human plasma that had undergone affinity chromatography to remove BMP9 homodimer. Finally, we provide evidence that hepatic stellate cells in the liver could be the source of the BMP9-BMP10 heterodimer. Together, our findings demonstrate that BMP9 and BMP10 can heterodimerize and that this heterodimer is responsible for most of the biological BMP activity found in plasma.
Collapse
Affiliation(s)
- Emmanuelle Tillet
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Marie Ouarné
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Agnès Desroches-Castan
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Christine Mallet
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Mariela Subileau
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Robin Didier
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Anna Lioutsko
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Guillaume Belthier
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Jean-Jacques Feige
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| | - Sabine Bailly
- From the University of Grenoble Alpes, Inserm, CEA, BIG-Biologie du Cancer et de l'Infection, 38000 Grenoble, France
| |
Collapse
|
14
|
Agosta C, Laugier J, Guyon L, Denis J, Bertherat J, Libé R, Boisson B, Sturm N, Feige JJ, Chabre O, Cherradi N. MiR-483-5p and miR-139-5p promote aggressiveness by targeting N-myc downstream-regulated gene family members in adrenocortical cancer. Int J Cancer 2018. [PMID: 29516499 DOI: 10.1002/ijc.31363] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Adrenocortical carcinoma (ACC) is a tumor with poor prognosis in which overexpression of a panel of microRNAs has been associated with malignancy but a very limited number of investigations on their role in ACC pathogenesis have been conducted. We examined the involvement of miR-483-5p and miR-139-5p in adrenocortical cancer aggressiveness. Using bioinformatics predictions and mRNA/miRNA expression profiles, we performed an integrated analysis to identify inversely correlated miRNA-mRNA pairs in ACC. We identified N-myc downstream-regulated gene family members 2 and 4 (NDRG2 and NDRG4) as targets of miR-483-5p and miR-139-5p, respectively. NDRG2 and NDRG4 expressions were inversely correlated respectively with miR-483-5p and miR-139-5p levels in aggressive ACC samples from two independent cohorts of 20 and 44 ACC. Moreover, upregulation of miR-139-5p and downregulation of NDRG4 demonstrated a striking prognostic value. A direct interaction between miR-483-5p or miR-139-5p and their targets was demonstrated in reporter assays. Downregulation of miR-483-5p or miR-139-5p in the ACC cell lines NCI-H295R and SW13 increased NDRG2 or NDRG4 mRNA and protein expression, compromised adrenocortical cancer cell invasiveness and anchorage-independent growth. MiR-483-5p or miR-139-5p overexpression and NDRG2 or NDRG4 inhibition produce similar changes, which are rescued by NDRG2 or NDRG4 ectopic expression. We established that key factors mediating epithelial-to-mesenchymal transition are downstream effectors of miR-483-5p/NDRG2 and miR-139-5p/NDRG4 pathways. Collectively, our data show for the first time that miR-483-5p/NDRG2 and miR-139-5p/NDRG4 axes promote ACC aggressiveness, with potential implications for prognosis and therapeutic interventions in adrenocortical malignancies.
Collapse
Affiliation(s)
- Claire Agosta
- Centre Hospitalier Universitaire Grenoble Alpes, Service d'Endocrinologie, Grenoble, France.,Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Commissariat à l'Energie Atomique, Biologie du Cancer et de l'Infection, Institut de Biosciences et Biotechnologies de Grenoble, Grenoble, France.,Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Jonathan Laugier
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Commissariat à l'Energie Atomique, Biologie du Cancer et de l'Infection, Institut de Biosciences et Biotechnologies de Grenoble, Grenoble, France.,Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Laurent Guyon
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Commissariat à l'Energie Atomique, Biologie du Cancer et de l'Infection, Institut de Biosciences et Biotechnologies de Grenoble, Grenoble, France.,Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Josiane Denis
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Commissariat à l'Energie Atomique, Biologie du Cancer et de l'Infection, Institut de Biosciences et Biotechnologies de Grenoble, Grenoble, France.,Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Jérôme Bertherat
- Université Paris Descartes, Paris, France.,Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique UMR 8104, Unité 1016, Institut Cochin, Paris, France.,Département d'Endocrinologie, Centre Expert Cancers Rares de la Surrénale, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Rossella Libé
- Université Paris Descartes, Paris, France.,Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique UMR 8104, Unité 1016, Institut Cochin, Paris, France.,Département d'Endocrinologie, Centre Expert Cancers Rares de la Surrénale, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | - Bruno Boisson
- Centre Hospitalier Universitaire Grenoble Alpes, Institut de Biologie et de Pathologie, Grenoble, France
| | - Nathalie Sturm
- Centre Hospitalier Universitaire Grenoble Alpes, Institut de Biologie et de Pathologie, Grenoble, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Commissariat à l'Energie Atomique, Biologie du Cancer et de l'Infection, Institut de Biosciences et Biotechnologies de Grenoble, Grenoble, France.,Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Olivier Chabre
- Centre Hospitalier Universitaire Grenoble Alpes, Service d'Endocrinologie, Grenoble, France.,Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Commissariat à l'Energie Atomique, Biologie du Cancer et de l'Infection, Institut de Biosciences et Biotechnologies de Grenoble, Grenoble, France.,Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Nadia Cherradi
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Commissariat à l'Energie Atomique, Biologie du Cancer et de l'Infection, Institut de Biosciences et Biotechnologies de Grenoble, Grenoble, France.,Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| |
Collapse
|
15
|
Arvin-Berod M, Desroches-Castan A, Bonte S, Brugière S, Couté Y, Guyon L, Feige JJ, Baussanne I, Demeunynck M. Indolizine-Based Scaffolds as Efficient and Versatile Tools: Application to the Synthesis of Biotin-Tagged Antiangiogenic Drugs. ACS Omega 2017; 2:9221-9230. [PMID: 30023604 PMCID: PMC6044919 DOI: 10.1021/acsomega.7b01184] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/18/2017] [Accepted: 11/28/2017] [Indexed: 06/08/2023]
Abstract
We describe the design and optimization of polyfunctional scaffolds based on a fluorescent indolizine core derivatized with various orthogonal groups (amines, esters, oximes, alkynes, etc.). To show one application as tools in biology, the scaffold was used to prepare drug-biotin conjugates that were then immobilized onto avidin-agarose for affinity chromatography. More specifically, the antiangiogenic drug COB223, whose mechanism of action remained unclear, was chosen as a proof-of-concept drug. The drug-selective discrimination of proteins observed after elution of the cell lysates through the affinity columns, functionalized either with the biologically active COB223 or a structurally related inactive analogue (COB236), is a clear indication that the presence of the indolizine core does not limit drug-protein interaction and confirms the usefulness of the indolizine scaffold. Furthermore, the separation of COB223-interacting proteins from human placental extracts unveiled unanticipated protein targets belonging to the family of regulatory RNA-binding proteins, which opens the way to new hypotheses on the mode of action of this antiangiogenic drug.
Collapse
Affiliation(s)
| | | | - Simon Bonte
- Univ.
Grenoble Alpes, CNRS, DPM, 38000 Grenoble, France
| | - Sabine Brugière
- Univ.
Grenoble Alpes, CEA, Inserm, BIG-BGE, 38000 Grenoble, France
| | - Yohann Couté
- Univ.
Grenoble Alpes, CEA, Inserm, BIG-BGE, 38000 Grenoble, France
| | - Laurent Guyon
- Univ.
Grenoble Alpes, Inserm, CEA, BIG-BCI, 38000, Grenoble, France
| | | | | | | |
Collapse
|
16
|
Abstract
The regulation of mRNA stability has emerged as a critical control step in dynamic gene expression. This process occurs in response to modifications of the cellular environment, including hormonal variations, and regulates the expression of subsets of proteins whose levels need to be rapidly adjusted. Modulation of messenger RNA stability is usually mediated by stabilizing or destabilizing RNA-binding proteins (RNA-BP) that bind to the 3'-untranslated region regulatory motifs, such as AU-rich elements (AREs). Destabilizing ARE-binding proteins enhance the decay of their target transcripts by recruiting the mRNA decay machineries. Failure of such mechanisms, in particular misexpression of RNA-BP, has been linked to several human diseases. In the adrenal cortex, the expression and activity of mRNA stability regulatory proteins are still understudied. However, ACTH- or cAMP-elicited changes in the expression/phosphorylation status of the major mRNA-destabilizing protein TIS11b/BRF1 or in the subcellular localization of the stabilizing protein Human antigen R have been reported. They suggest that this level of regulation of gene expression is also important in endocrinology.
Collapse
Affiliation(s)
- Agnès Desroches-Castan
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Grenoble, France
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l’Infection, Grenoble, France
- Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Grenoble, France
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l’Infection, Grenoble, France
- Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
| | - Nadia Cherradi
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Grenoble, France
- Commissariat à l’Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l’Infection, Grenoble, France
- Université Grenoble Alpes, Unité Mixte de Recherche-S1036, Grenoble, France
- *Correspondence: Nadia Cherradi,
| |
Collapse
|
17
|
Rataj F, Planel S, Desroches-Castan A, Le Douce J, Lamribet K, Denis J, Feige JJ, Cherradi N. The cAMP pathway regulates mRNA decay through phosphorylation of the RNA-binding protein TIS11b/BRF1. Mol Biol Cell 2016; 27:3841-3854. [PMID: 27708140 PMCID: PMC5170607 DOI: 10.1091/mbc.e16-06-0379] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Revised: 09/29/2016] [Accepted: 09/30/2016] [Indexed: 02/01/2023] Open
Abstract
TIS11b belongs to the tristetraprolin family of zinc-finger proteins, which target short-lived mRNA for degradation. This study shows that the cAMP pathway up-regulates TIS11b expression and modulates its function in mRNA decay through PKA-dependent phosphorylation of two highly conserved phosphosites. TPA-inducible sequence 11b/butyrate response factor 1 (TIS11b/BRF1) belongs to the tristetraprolin (TTP) family of zinc-finger proteins, which bind to mRNAs containing AU-rich elements in their 3′-untranslated region and target them for degradation. Regulation of TTP family function through phosphorylation by p38 MAP kinase and Akt/protein kinase B signaling pathways has been extensively studied. In contrast, the role of cAMP-dependent protein kinase (PKA) in the control of TTP family activity in mRNA decay remains largely unknown. Here we show that PKA activation induces TIS11b gene expression and protein phosphorylation. Site-directed mutagenesis combined with kinase assays and specific phosphosite immunodetection identified Ser-54 (S54) and Ser-334 (S334) as PKA target amino acids in vitro and in vivo. Phosphomimetic mutation of the C-terminal S334 markedly increased TIS11b half-life and, unexpectedly, enhanced TIS11b activity on mRNA decay. Examination of protein–protein interactions between TIS11b and components of the mRNA decay machinery revealed that mimicking phosphorylation at S334 enhances TIS11b interaction with the decapping coactivator Dcp1a, while preventing phosphorylation at S334 potentiates its interaction with the Ccr4-Not deadenylase complex subunit Cnot1. Collectively our findings establish for the first time that cAMP-elicited phosphorylation of TIS11b plays a key regulatory role in its mRNA decay-promoting function.
Collapse
Affiliation(s)
- Felicitas Rataj
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| | - Séverine Planel
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| | - Agnès Desroches-Castan
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| | - Juliette Le Douce
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| | - Khadija Lamribet
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| | - Josiane Denis
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| | - Nadia Cherradi
- Institut National de la Santé et de la Recherche Médicale, INSERM U1036, Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biosciences et Biotechnologies de Grenoble, Laboratoire Biologie du Cancer et de l'Infection, and Université Grenoble Alpes, Unité Mixte de Recherche-S1036, F-38000 Grenoble, France
| |
Collapse
|
18
|
Sergent F, Hoffmann P, Brouillet S, Garnier V, Salomon A, Murthi P, Benharouga M, Feige JJ, Alfaidy N. Sustained Endocrine Gland-Derived Vascular Endothelial Growth Factor Levels Beyond the First Trimester of Pregnancy Display Phenotypic and Functional Changes Associated With the Pathogenesis of Pregnancy-Induced Hypertension. Hypertension 2016; 68:148-56. [PMID: 27141059 DOI: 10.1161/hypertensionaha.116.07442] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 04/01/2016] [Indexed: 12/14/2022]
Abstract
Pregnancy-induced hypertension diseases are classified as gestational hypertension, preeclampsia, or eclampsia. The mechanisms of their development and prediction are still to be discovered. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor secreted by the placenta during the first trimester of human pregnancy that was shown to control trophoblast invasion, to be upregulated by hypoxia, and to be abnormally elevated in pathological pregnancies complicated with preeclampsia and intrauterine growth restriction. These findings suggested that sustaining EG-VEGF levels beyond the first trimester of pregnancy may contribute to pregnancy-induced hypertension. To test this hypothesis, osmotic minipumps delivering EG-VEGF were implanted subcutaneously into gravid OF1 (Oncins France 1) mice on day 11.5 post coitus, which is equivalent to the end of the first trimester of human pregnancy. Mice were euthanized at 15.5 and 18.5 days post coitus to assess (1) litter size, placental, and fetal weights; (2) placental histology and function; (3) maternal blood pressure; (4) renal histology and function; and (5) circulating soluble fms-like tyrosine kinase 1 and soluble endoglin. Increased EG-VEGF levels caused significant defects in placental organization and function. Both increased hypoxia and decreased trophoblast invasion were observed. Treated mice had elevated circulating soluble fms-like tyrosine kinase 1 and soluble endoglin and developed gestational hypertension with dysregulated maternal kidney function. EG-VEGF effect on the kidney function was secondary to its effects on the placenta as similarly treated male mice had normal kidney functions. Altogether, these data provide a strong evidence to confirm that sustained EG-VEGF beyond the first trimester of pregnancy contributes to the development of pregnancy-induced hypertension.
Collapse
Affiliation(s)
- Frédéric Sergent
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Pascale Hoffmann
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Sophie Brouillet
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Vanessa Garnier
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Aude Salomon
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Padma Murthi
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Mohamed Benharouga
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Jean-Jacques Feige
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| | - Nadia Alfaidy
- From the Institut National de la Santé et de la Recherche Médicale, Grenoble, France (F.S., P.H., S.B., V.G., A.S., J.-J.F., N.A.); University Grenoble-Alpes, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Commissariat à l'Energie Atomique (CEA), BIG (Biosciences Biotechnology Institute of Grenoble)-Biology of Cancer and Infection, Grenoble, France (F.S., P.H., S.B., V.G., A.S., M.B., J.-J.F., N.A.); Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France (P.H.); Laboratoire d'Aide à la Procréation-CECOS, University Hospital of Grenoble, La Tronche, France (S.B.); Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France (M.B.); and Department of Medicine, School of Clinical Sciences, Monash university and the Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia (P.M.)
| |
Collapse
|
19
|
Alfaidy N, Hoffmann P, Gillois P, Gueniffey A, Lebayle C, Garçin H, Thomas-Cadi C, Bessonnat J, Coutton C, Villaret L, Quenard N, Bergues U, Feige JJ, Hennebicq S, Brouillet S. PROK1 Level in the Follicular Microenvironment: A New Noninvasive Predictive Biomarker of Embryo Implantation. J Clin Endocrinol Metab 2016; 101:435-44. [PMID: 26401590 DOI: 10.1210/jc.2015-1988] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Prokineticin 1 (PROK1), also called endocrine gland-derived vascular endothelial growth factor, is a well-established regulator of endometrial receptivity and placental development. However, its clinical usefulness as a noninvasive predictive biomarker of embryo implantation is yet to be validated. OBJECTIVE The main objective of this article was to determine the relationship between PROK1 levels in the follicular fluid (FF) and fertilization culture media (FCM) and the reproductive outcome in patients who received a first conventional in vitro fertilization-embryo transfer. The secondary objective was to characterize the expression of PROK1 and its receptors (PROKRs) in the human follicular microenvironment. DESIGN AND SETTING We conducted a prospective study between January 2013 and June 2015 at the University Hospital of Grenoble. PATIENTS A total of 135 infertile in vitro fertilization patients and 10 women undergoing ovarian tissue cryopreservation were included. INTERVENTIONS The PROK1 concentration was measured by ELISA in FF and FCM collected on the day of oocyte retrieval and the day of the oocyte denudation step, respectively. Follicular expression of the PROK1/PROKR system was determined by immunohistochemistry, RT-quantitative PCR, and ELISA. MAIN OUTCOME MEASURE Assessment of the clinical pregnancy rates was the main outcome. RESULTS FF and FCM PROK1 levels were significantly higher in the embryo implantation group (P < .001) and were predictive of subsequent embryo implantation (area under the receiver operating characteristic curve, 0.91 [95% confidence interval, 0.81-1.00], P = .001; and 0.88 [0.72-1.00], P = .001, respectively). FF and FCM PROK1 levels remain similar irrespective of the embryo morphokinetic parameters (P = .71 and P = .83, respectively). The PROK1/PROKR system is expressed during human folliculogenesis. CONCLUSIONS PROK1 levels in FF and FCM could constitute new predictive noninvasive markers of successful embryo implantation in conventional in vitro fertilization-embryo transfer.
Collapse
Affiliation(s)
- Nadia Alfaidy
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Pascale Hoffmann
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Pierre Gillois
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Aurore Gueniffey
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Camille Lebayle
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Héloïse Garçin
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Claire Thomas-Cadi
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Julien Bessonnat
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Charles Coutton
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Laure Villaret
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Nicole Quenard
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Ulrike Bergues
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Jean-Jacques Feige
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Sylviane Hennebicq
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| | - Sophie Brouillet
- Université Grenoble-Alpes (N.A., P.H., P.G., A.G., C.L., H.C., J.B., C.C., J.-J.F., S.H., S.B.), 38000 Grenoble, France; Centre Hospitalier Universitaire de Grenoble (A.G., C.T.-C., J.B., L.V., N.Q., U.B., S.H., S.B.), Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation-CECOS, 38700 La Tronche, France; INSERM (N.A., P.H., J.-J.F., S.B.), Unité 1036, Biologie du Cancer et de l'Infection, 38000 Grenoble, France; Commissariat à l'Energie Atomique (N.A., P.H., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant, Laboratoire BCI, 38000 Grenoble, France; Equipe "Génétique, Epigénétique et Thérapies de l'Infertilité" Institut Albert Bonniot (J.B., C.C., S.H.), INSERM U823, Grenoble F-38000, France; Centre National de la Recherche Scientifique (P.G.), Unité Mixte de Recherche 5525, Techniques For Biomedical Engineering and Complexity Management-Informatics, Mathematics and Applications, Themas, 38000 Grenoble, France; and Centre Hospitalier Universitaire de Grenoble (C.C.), Hôpital Couple Enfant, Département de Génétique et Procréation, Laboratoire de Génétique Chromosomique, 38700 La Tronche, France
| |
Collapse
|
20
|
Desroches-Castan A, Quélard D, Demeunynck M, Constant JF, Dong C, Keramidas M, Coll JL, Barette C, Lafanechère L, Feige JJ. A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras. Oncotarget 2016; 6:5382-411. [PMID: 25742784 PMCID: PMC4467156 DOI: 10.18632/oncotarget.2979] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 12/19/2014] [Indexed: 02/07/2023] Open
Abstract
The efficacy of anti-angiogenic therapies on cancer patients is limited by the emergence of drug resistance, urging the search for second-generation drugs. In this study, we screened an academic chemical library (DCM, University of Grenoble-Alpes) and identified a leader molecule, COB223, that inhibits endothelial cell migration and proliferation. It inhibits also Lewis lung carcinoma (LLC/2) cell proliferation whereas it does not affect fibroblast proliferation. The anti-angiogenic activity of COB223 was confirmed using several in vitro and in vivo assays. In a mouse LLC/2 tumor model, ip administration of doses as low as 4 mg/kg COB223 efficiently reduced the tumor growth rate. We observed that COB223 inhibits endothelial cell ERK1/2 phosphorylation induced by VEGF, FGF-2 or serum and that it acts downstream of PKC and upstream of Ras. This molecule represents a novel anti-angiogenic and anti-tumorigenic agent with an original mechanism of action that deserves further development as an anti-cancer drug.
Collapse
Affiliation(s)
- Agnès Desroches-Castan
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| | - Delphine Quélard
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Janssen, Pharmaceutical Companies of Johnson and Johnson, Issy-les-Moulineaux, F-92130, France
| | - Martine Demeunynck
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5063, Department of Molecular Pharmacochemistry, Grenoble, F-38041, France
| | - Jean-François Constant
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Chongling Dong
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Michelle Keramidas
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Luc Coll
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Caroline Barette
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1038, Large Scale Biology, Grenoble, F-38054, France
| | - Laurence Lafanechère
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| |
Collapse
|
21
|
Dakouane-Giudicelli M, Brouillet S, Traboulsi W, Torre A, Vallat G, Si Nacer S, Vallée M, Feige JJ, Alfaidy N, de Mazancourt P. Inhibition of human placental endothelial cell proliferation and angiogenesis by netrin-4. Placenta 2015; 36:1260-5. [PMID: 26390805 DOI: 10.1016/j.placenta.2015.09.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2015] [Revised: 09/09/2015] [Accepted: 09/11/2015] [Indexed: 10/23/2022]
Abstract
INTRODUCTION Netrin-4 is a secreted member of the laminin-related protein family, known to be involved in axonal guidance and endothelial cell survival, proliferation, and migration. We have recently reported the cellular localization of netrin-4 and its receptor neogenin in human first trimester and term placenta. A strong expression of netrin-4 was observed in trophoblast and in endothelial cells, suggesting a potential role of this protein in placental angiogenesis. In relation to human pregnancy, it has been reported that circulating netrin-4 were increased in fetal umbilical cord blood of intrauterine growth restriction IUGR compared to normal pregnancy suggesting an adverse effect of this protein on placental and fetal development. The aim of this study was to determine the role of netrin-4 in placental angiogenesis. METHODS The effects of netrin-4 on proliferation, migration, tube-like organization, and spheroid sprouting of human placental microvascular endothelial cells (HPEC) were studied. RESULTS We demonstrated that netrin-4 inhibits HPEC proliferation, tube-like formation, migration and spheroid sprouting, suggesting a direct role of netrin-4 in the regulation of intra-villus angiogenesis. DISCUSSION This is the first report of an anti-angiogenic activity of netrin-4 in human placenta. This study brings new insights into netrin-4 roles in placental angiogenesis and suggests possible involvements of netrin-4 in angiogenesis-related pathologies such as IUGR.
Collapse
Affiliation(s)
- M Dakouane-Giudicelli
- Institut National de la Santé et de la Recherche Médicale, Unité 1179, Montigny Le Bretonneux, France; Université de Versailles Saint Quentin, En Yvelines, France.
| | - S Brouillet
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France; Commissariat à l'Energie Atomique (CEA), iRTSV-Biology of Cancer and Infection, Grenoble, France; Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation, 38700 La Tronche, France
| | - W Traboulsi
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France
| | - A Torre
- Université de Versailles Saint Quentin, En Yvelines, France
| | - G Vallat
- Université de Versailles Saint Quentin, En Yvelines, France
| | - S Si Nacer
- Université de Versailles Saint Quentin, En Yvelines, France
| | - M Vallée
- Université de Versailles Saint Quentin, En Yvelines, France
| | - J J Feige
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France; Commissariat à l'Energie Atomique (CEA), iRTSV-Biology of Cancer and Infection, Grenoble, France
| | - N Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, 38000 Grenoble, France; Commissariat à l'Energie Atomique (CEA), iRTSV-Biology of Cancer and Infection, Grenoble, France
| | - P de Mazancourt
- Institut National de la Santé et de la Recherche Médicale, Unité 1179, Montigny Le Bretonneux, France; Université de Versailles Saint Quentin, En Yvelines, France; AP-HP Hopital Ambroise Paré, Boulogne-Billancourt, France
| |
Collapse
|
22
|
Garnier V, Traboulsi W, Salomon A, Brouillet S, Fournier T, Winkler C, Desvergne B, Hoffmann P, Zhou QY, Congiu C, Onnis V, Benharouga M, Feige JJ, Alfaidy N. PPARγ controls pregnancy outcome through activation of EG-VEGF: new insights into the mechanism of placental development. Am J Physiol Endocrinol Metab 2015; 309:E357-69. [PMID: 26081281 DOI: 10.1152/ajpendo.00093.2015] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Accepted: 06/04/2015] [Indexed: 01/29/2023]
Abstract
PPARγ-deficient mice die at E9.5 due to placental abnormalities. The mechanism by which this occurs is unknown. We demonstrated that the new endocrine factor EG-VEGF controls the same processes as those described for PPARγ, suggesting potential regulation of EG-VEGF by PPARγ. EG-VEGF exerts its functions via prokineticin receptor 1 (PROKR1) and 2 (PROKR2). This study sought to investigate whether EG-VEGF mediates part of PPARγ effects on placental development. Three approaches were used: 1) in vitro, using human primary isolated cytotrophoblasts and the extravillous trophoblast cell line (HTR-8/SVneo); 2) ex vivo, using human placental explants (n = 46 placentas); and 3) in vivo, using gravid wild-type PPARγ(+/-) and PPARγ(-/-) mice. Major processes of placental development that are known to be controlled by PPARγ, such as trophoblast proliferation, migration, and invasion, were assessed in the absence or presence of PROKR1 and PROKR2 antagonists. In both human trophoblast cell and placental explants, we demonstrated that rosiglitazone, a PPARγ agonist, 1) increased EG-VEGF secretion, 2) increased EG-VEGF and its receptors mRNA and protein expression, 3) increased placental vascularization via PROKR1 and PROKR2, and 4) inhibited trophoblast migration and invasion via PROKR2. In the PPARγ(-/-) mouse placentas, EG-VEGF levels were significantly decreased, supporting an in vivo control of EG-VEGF/PROKRs system during pregnancy. The present data reveal EG-VEGF as a new mediator of PPARγ effects during pregnancy and bring new insights into the fine mechanism of trophoblast invasion.
Collapse
Affiliation(s)
- Vanessa Garnier
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, Grenoble, France; iRTSV-Biology of Cancer and Infection, Commissariat à l'Energie Atomique, Grenoble, France
| | - Wael Traboulsi
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, Grenoble, France; iRTSV-Biology of Cancer and Infection, Commissariat à l'Energie Atomique, Grenoble, France
| | - Aude Salomon
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, Grenoble, France; iRTSV-Biology of Cancer and Infection, Commissariat à l'Energie Atomique, Grenoble, France
| | - Sophie Brouillet
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, Grenoble, France; iRTSV-Biology of Cancer and Infection, Commissariat à l'Energie Atomique, Grenoble, France; Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
| | - Thierry Fournier
- Institut National de la Santé et de la Recherche Médicale, UMR-S 1139, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; PremUP Foundation, Paris, France
| | - Carine Winkler
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
| | - Beatrice Desvergne
- Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
| | - Pascale Hoffmann
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, Grenoble, France; iRTSV-Biology of Cancer and Infection, Commissariat à l'Energie Atomique, Grenoble, France; Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France; and
| | - Qun-Yong Zhou
- Department of Pharmacology, University of California-Irvine, Irvine, California
| | - Cenzo Congiu
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
| | - Valentina Onnis
- Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy
| | - Mohamed Benharouga
- Laboratoire de Chimie et Biologie des Métaux, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Grenoble, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, Grenoble, France; iRTSV-Biology of Cancer and Infection, Commissariat à l'Energie Atomique, Grenoble, France
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France; Université Grenoble-Alpes, Grenoble, France; iRTSV-Biology of Cancer and Infection, Commissariat à l'Energie Atomique, Grenoble, France;
| |
Collapse
|
23
|
Murthi P, Brouillet S, Pratt A, Borg A, Kalionis B, Goffin F, Tsatsaris V, Munaut C, Feige JJ, Benharouga M, Fournier T, Alfaidy N. An EG-VEGF-Dependent Decrease in Homeobox Gene NKX3.1 Contributes to Cytotrophoblast Dysfunction: A Possible Mechanism in Human Fetal Growth Restriction. Mol Med 2015. [PMID: 26208047 DOI: 10.2119/molmed.2015.00071] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Idiopathic fetal growth restriction (FGR) is frequently associated with placental insufficiency. Previous reports have provided evidence that endocrine gland-derived vascular endothelial growth factor (EG-VEGF), a placental secreted protein, is expressed during the first trimester of pregnancy, controls both trophoblast proliferation and invasion, and its increased expression is associated with human FGR. In this study, we hypothesize that EG-VEGF-dependent changes in placental homeobox gene expressions contribute to trophoblast dysfunction in idiopathic FGR. The changes in EG-VEGF-dependent homeobox gene expressions were determined using a homeobox gene cDNA array on placental explants of 8-12 wks gestation after stimulation with EG-VEGF in vitro for 24 h. The homeobox gene array identified a greater-than-five-fold increase in HOXA9, HOXC8, HOXC10, HOXD1, HOXD8, HOXD9 and HOXD11, while NKX 3.1 showed a greater-than-two-fold decrease in mRNA expression compared with untreated controls. Homeobox gene NKX3.1 was selected as a candidate because it is a downstream target of EG-VEGF and its expression and functional roles are largely unknown in control and idiopathic FGR-affected placentae. Real-time PCR and immunoblotting showed a significant decrease in NKX3.1 mRNA and protein levels, respectively, in placentae from FGR compared with control pregnancies. Gene inactivation in vitro using short-interference RNA specific for NKX3.1 demonstrated an increase in BeWo cell differentiation and a decrease in HTR-8/SVneo proliferation. We conclude that the decreased expression of homeobox gene NKX3.1 downstream of EG-VEGF may contribute to the trophoblast dysfunction associated with idiopathic FGR pregnancies.
Collapse
Affiliation(s)
- Padma Murthi
- Department of Perinatal Medicine Pregnancy Research Centre, The Royal Women's Hospital and The University of Melbourne Department of Obstetrics and Gynaecology, The Royal Women's Hospital, Victoria, Australia.,Department of Medicine, Monash University, Victoria, Australia
| | - Sophie Brouillet
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Université Grenoble-Alpes, Grenoble, France.,Commissariat à L'Energie Atomique (CEA), iRTSV-Biology of Cancer and Infection, Grenoble, France.,Centre Hospitalier Universitaire de Grenoble, Hôpital Couple-Enfant, Centre Clinique et Biologique d'Assistance Médicale à la Procréation, La Tronche, France
| | - Anita Pratt
- Department of Perinatal Medicine Pregnancy Research Centre, The Royal Women's Hospital and The University of Melbourne Department of Obstetrics and Gynaecology, The Royal Women's Hospital, Victoria, Australia
| | - Anthony Borg
- Department of Perinatal Medicine Pregnancy Research Centre, The Royal Women's Hospital and The University of Melbourne Department of Obstetrics and Gynaecology, The Royal Women's Hospital, Victoria, Australia
| | - Bill Kalionis
- Department of Perinatal Medicine Pregnancy Research Centre, The Royal Women's Hospital and The University of Melbourne Department of Obstetrics and Gynaecology, The Royal Women's Hospital, Victoria, Australia
| | - Frederic Goffin
- Laboratory of Tumor and Developmental Biology, University of Liège, Belgium
| | - Vassilis Tsatsaris
- Department of Obstetrics and Gynecology, Hôpital Cochin, Maternité Port-Royal, Université Rene Descartes, Paris, France
| | - Carine Munaut
- Laboratory of Tumor and Developmental Biology, University of Liège, Belgium
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Université Grenoble-Alpes, Grenoble, France.,Commissariat à L'Energie Atomique (CEA), iRTSV-Biology of Cancer and Infection, Grenoble, France
| | - Mohamed Benharouga
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5249, Laboratoire de Chimie et Biologie des Métaux, Grenoble, France
| | - Thierry Fournier
- INSERM, U1139; Universite Paris Descartes, UMR-S1139; and PremUp Foundation, Paris, France
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Grenoble, France.,Université Grenoble-Alpes, Grenoble, France.,Commissariat à L'Energie Atomique (CEA), iRTSV-Biology of Cancer and Infection, Grenoble, France
| |
Collapse
|
24
|
Chauvet S, Traboulsi W, Thevenon L, Kouadri A, Feige JJ, Camara B, Alfaidy N, Benharouga M. EG-VEGF, BV8, and their receptor expression in human bronchi and their modification in cystic fibrosis: Impact of CFTR mutation (delF508). Am J Physiol Lung Cell Mol Physiol 2015; 309:L314-22. [PMID: 26047640 DOI: 10.1152/ajplung.00382.2014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 05/22/2015] [Indexed: 12/22/2022] Open
Abstract
Enhanced lung angiogenesis has been reported in cystic fibrosis (CF). Recently, two highly homologous ligands, endocrine gland vascular endothelial growth factor (EG-VEGF) and mammalian Bv8, have been described as new angiogenic factors. Both ligands bind and activate two closely related G protein-coupled receptors, the prokineticin receptor (PROKR) 1 and 2. Yet, the expression, regulation, and potential role of EG-VEGF, BV8, and their receptors in normal and CF lung are still unknown. The expression of the receptors and their ligands was examined using molecular, biochemical, and immunocytochemistry analyses in lungs obtained from CF patients vs. control and in normal and CF bronchial epithelial cells. Cystic fibrosis transmembrane conductance regulator (CFTR) activity was evaluated in relation to both ligands, and concentrations of EG-VEGF were measured by ELISA. At the mRNA level, EG-VEGF, BV8, and PROKR2 gene expression was, respectively, approximately five, four, and two times higher in CF lungs compared with the controls. At the cellular level, both the ligands and their receptors showed elevated expressions in the CF condition. Similar results were observed at the protein level. The EG-VEGF secretion was apical and was approximately two times higher in CF compared with the normal epithelial cells. This secretion was increased following the inhibition of CFTR chloride channel activity. More importantly, EG-VEGF and BV8 increased the intracellular concentration of Ca(2+) and cAMP and stimulated CFTR-chloride channel activity. Altogether, these data suggest local roles for epithelial BV8 and EG-VEGF in the CF airway peribronchial vascular remodeling and highlighted the role of CFTR activity in both ligand biosynthesis and secretion.
Collapse
Affiliation(s)
- Sylvain Chauvet
- Centre National de la Recherche Scientifique, LCBM-UMR 5249, Grenoble, France; Commissariat à l'Energie Atomique, DSV-iRTSV, Grenoble, France; Grenoble Alpes Université, Grenoble, France
| | - Wael Traboulsi
- Commissariat à l'Energie Atomique, DSV-iRTSV, Grenoble, France; Grenoble Alpes Université, Grenoble, France; Institut National de la Santé et de la Recherche Médicale, U1036, Grenoble, France; and
| | - Laura Thevenon
- Commissariat à l'Energie Atomique, DSV-iRTSV, Grenoble, France; Grenoble Alpes Université, Grenoble, France; Institut National de la Santé et de la Recherche Médicale, U1036, Grenoble, France; and
| | - Amal Kouadri
- Centre National de la Recherche Scientifique, LCBM-UMR 5249, Grenoble, France; Commissariat à l'Energie Atomique, DSV-iRTSV, Grenoble, France; Grenoble Alpes Université, Grenoble, France
| | - Jean-Jacques Feige
- Commissariat à l'Energie Atomique, DSV-iRTSV, Grenoble, France; Grenoble Alpes Université, Grenoble, France; Institut National de la Santé et de la Recherche Médicale, U1036, Grenoble, France; and
| | - Boubou Camara
- Centre de Ressources et de Compétences pour la Mucoviscidose, Clinique Universitaire de Pneumologie-Pole Thorax et Vaisseaux, CHU de Grenoble, France
| | - Nadia Alfaidy
- Commissariat à l'Energie Atomique, DSV-iRTSV, Grenoble, France; Grenoble Alpes Université, Grenoble, France; Institut National de la Santé et de la Recherche Médicale, U1036, Grenoble, France; and
| | - Mohamed Benharouga
- Centre National de la Recherche Scientifique, LCBM-UMR 5249, Grenoble, France; Commissariat à l'Energie Atomique, DSV-iRTSV, Grenoble, France; Grenoble Alpes Université, Grenoble, France;
| |
Collapse
|
25
|
Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S, Tillet E. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Hum Mol Genet 2014; 24:1142-54. [PMID: 25312062 DOI: 10.1093/hmg/ddu531] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant inheritable vascular dysplasia caused by mutations in genes encoding either endoglin or activin receptor-like kinase-1 (ALK1). Functional significance of endoglin missense mutations remains largely unknown leading to a difficult discrimination between polymorphisms and pathogenic mutations. In order to study the functional significance of endoglin mutations and to help HHT1 diagnosis, we developed a cellular assay based on the ability of endoglin to enhance ALK1 response to bone morphogenetic protein 9 (BMP9). We generated and characterized 31 distinct ENG mutants reproducing human HHT1 missense mutations identified in patients of the Molecular Genetics Department in Lyon. We found that 16 mutants behaved like wild-type (WT) endoglin, and thus corresponded to benign rare variants. The 15 other variants showed defects in BMP9 response and were identified as pathogenic mutations. Interestingly, two mutants (S278P and F282V) had lost their ability to bind BMP9, identifying two crucial amino acids for BMP9 binding to endoglin. For all the others, the functional defect was correlated with a defective trafficking to the cell surface associated with retention in the endoplasmic reticulum. Further, we demonstrated that some intracellular mutants dimerized with WT endoglin and impaired its cell-surface expression thus acting as dominant-negatives. Taken together, we show that endoglin loss-of-function can result from different mechanisms in HHT1 patients. We also provide a diagnostic tool helping geneticists in screening for novel or conflicting ENG mutations.
Collapse
Affiliation(s)
- Christine Mallet
- Inserm, U1036, Grenoble F-38000, France, CEA, DSV, iRTSV, Laboratoire Biologie du Cancer et de L'Infection, Grenoble F-38000, France, University Grenoble-Alpes, Grenoble F-38000, France
| | - Khadija Lamribet
- Inserm, U1036, Grenoble F-38000, France, CEA, DSV, iRTSV, Laboratoire Biologie du Cancer et de L'Infection, Grenoble F-38000, France, University Grenoble-Alpes, Grenoble F-38000, France
| | - Sophie Giraud
- Hôpital Edouard Herriot Service de Génétique Moléculaire et Clinique, Lyon, France and
| | - Sophie Dupuis-Girod
- Hospices Civils de Lyon, Hôpital Louis Pradel, Genetic Department and National Reference Center for Rendu-Osler Disease, France
| | - Jean-Jacques Feige
- Inserm, U1036, Grenoble F-38000, France, CEA, DSV, iRTSV, Laboratoire Biologie du Cancer et de L'Infection, Grenoble F-38000, France, University Grenoble-Alpes, Grenoble F-38000, France
| | - Sabine Bailly
- Inserm, U1036, Grenoble F-38000, France, CEA, DSV, iRTSV, Laboratoire Biologie du Cancer et de L'Infection, Grenoble F-38000, France, University Grenoble-Alpes, Grenoble F-38000, France
| | - Emmanuelle Tillet
- Inserm, U1036, Grenoble F-38000, France, CEA, DSV, iRTSV, Laboratoire Biologie du Cancer et de L'Infection, Grenoble F-38000, France, University Grenoble-Alpes, Grenoble F-38000, France,
| |
Collapse
|
26
|
Traboulsi W, Bouffetal H, Aboussaouira T, Samouh N, Benharouga M, Feige JJ, Alfaidy N. EG-VEGF and its receptors are deregulated in complete hydatiform moles: Potential role in placental tumor development. Placenta 2014. [DOI: 10.1016/j.placenta.2014.06.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Abstract
During the last decade, there has been growing evidence for the involvement of prokineticins and their receptors (PROK/PROKR) in human reproduction, with multiple roles in the female and male reproductive systems. The PROK/PROKR signalling complex has been reported as a new actor in ovary, uterus, placenta, and testis physiology, with marked dysfunction in various pathological conditions such as polycystic ovary syndrome, recurrent pregnancy loss, preeclampsia, and ectopic pregnancy. Altogether, the results strongly suggest the involvement of prokineticins in spermatogenesis, oocyte competence, embryo implantation, pregnancy, and delivery, and argue for the clinical relevance of these cytokines and their receptors as diagnostic markers for several reproductive diseases.
Collapse
Affiliation(s)
- Sophie Brouillet
- Centre hospitalier universitaire de Grenoble, hôpital couple-enfant, centre d'aide médicale à la procréation, CS 10217, 38043 Grenoble Cedex 9, France - Inserm U1036, biologie du cancer et de l'infection, iRTSV, CEA Grenoble, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France - Commissariat à l'énergie atomique, institut de recherche en technologie et sciences pour le vivant, 38054 Grenoble Cedex 9, France - Université Grenoble-Alpes, 38041 Grenoble, France
| | - Pascale Hoffmann
- Centre hospitalier universitaire de Grenoble, hôpital couple-enfant, centre d'aide médicale à la procréation, CS 10217, 38043 Grenoble Cedex 9, France - Inserm U1036, biologie du cancer et de l'infection, iRTSV, CEA Grenoble, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France - Commissariat à l'énergie atomique, institut de recherche en technologie et sciences pour le vivant, 38054 Grenoble Cedex 9, France - Université Grenoble-Alpes, 38041 Grenoble, France
| | - Nadia Alfaidy
- Inserm U1036, biologie du cancer et de l'infection, iRTSV, CEA Grenoble, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France - Commissariat à l'énergie atomique, institut de recherche en technologie et sciences pour le vivant, 38054 Grenoble Cedex 9, France - Université Grenoble-Alpes, 38041 Grenoble, France
| | - Jean-Jacques Feige
- Inserm U1036, biologie du cancer et de l'infection, iRTSV, CEA Grenoble, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France - Commissariat à l'énergie atomique, institut de recherche en technologie et sciences pour le vivant, 38054 Grenoble Cedex 9, France - Université Grenoble-Alpes, 38041 Grenoble, France
| |
Collapse
|
28
|
Prudent R, Vassal-Stermann É, Nguyen CH, Mollaret M, Viallet J, Desroches-Castan A, Martinez A, Barette C, Pillet C, Valdameri G, Soleilhac E, Di Pietro A, Feige JJ, Billaud M, Florent JC, Lafanechère L. Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities. Br J Pharmacol 2013; 168:673-85. [PMID: 23004938 DOI: 10.1111/j.1476-5381.2012.02230.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Revised: 07/20/2012] [Accepted: 08/10/2012] [Indexed: 01/23/2023] Open
Abstract
BACKGROUND AND PURPOSE Drugs targeting microtubules are commonly used for cancer treatment. However, the potency of microtubule inhibitors used clinically is limited by the emergence of resistance. We thus designed a strategy to find new cell-permeable microtubule-targeting agents. EXPERIMENTAL APPROACH Using a cell-based assay designed to probe for microtubule polymerization status, we screened a chemical library and identified two azaindole derivatives, CM01 and CM02, as cell-permeable microtubule-depolymerizing agents. The mechanism of the anti-tumour effects of these two compounds was further investigated both in vivo and in vitro. KEY RESULTS CM01 and CM02 induced G2/M cell cycle arrest and exerted potent cytostatic effects on several cancer cell lines including multidrug-resistant (MDR) cell lines. In vitro experiments revealed that the azaindole derivatives inhibited tubulin polymerization and competed with colchicines for this effect, strongly indicating that tubulin is the cellular target of these azaindole derivatives. In vivo experiments, using a chicken chorioallantoic xenograft tumour assay, established that these compounds exert a potent anti-tumour effect. Furthermore, an assay probing the growth of vessels out of endothelial cell spheroids showed that CM01 and CM02 exert anti-angiogenic activities. CONCLUSIONS AND IMPLICATIONS CM01 and CM02 are reversible microtubule-depolymerizing agents that exert potent cytostatic effects on human cancer cells of diverse origins, including MDR cells. They were also shown to inhibit angiogenesis and tumour growth in chorioallantoic breast cancer xenografts. Hence, these azaindole derivatives are attractive candidates for further preclinical investigations.
Collapse
Affiliation(s)
- Renaud Prudent
- Institut Albert Bonniot, CRI INSERM/UJF U823, La Tronche Cedex, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Alfaidy N, Chauvet S, Donadio-Andrei S, Salomon A, Saoudi Y, Richaud P, Aude-Garcia C, Hoffmann P, Andrieux A, Moulis JM, Feige JJ, Benharouga M. Prion protein expression and functional importance in developmental angiogenesis: role in oxidative stress and copper homeostasis. Antioxid Redox Signal 2013; 18:400-11. [PMID: 22861352 DOI: 10.1089/ars.2012.4637] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
AIM It has been convincingly shown that oxidative stress and toxicity by deregulated metals, such as copper (Cu), are tightly linked to the development of pre-eclampsia and intrauterine growth retardation (IUGR), the most threatening pathologies of human pregnancy. However, mechanisms implemented to control these effects are far from being understood. Among proteins that bind Cu and insure cellular protection against oxidative stress is the cellular prion protein (PrP(C)), a glycosyl phosphatidyl inositol-anchored glycoprotein, which we reported to be highly expressed in human placenta. Herein, we investigated the pathophysiological role of PrP(C) in Cu and oxidative stress homeostasis in vitro using human placenta and trophoblast cells, and in vivo using three strains of mice (C57Bl6, PrP(C) knockout mice [PrP(-/-)], and PrP(C) overexpressing mice [Tga20]). RESULTS At the cellular level, PrP(C) protection against oxidative stress was established in multiple angiogenic processes: proliferation, migration, and tube-like organization. For the animal models, lack (PrP(-/-)) or overexpression (Tga20) of PrP(C) in gravid mice caused severe IUGR that was correlated with a decrease in litter size, changes in Cu homeostasis, increase in oxidative stress response, development of hypoxic environment, failure in placental function, and maintenance of growth defects of the offspring even 7.5 months after delivery. INNOVATION PrP(C) could serve as a marker for the idiopathic IUGR disease. CONCLUSION These findings demonstrate the stress-protective role of PrP(C) during development, and propose PrP(C) dysregulation as a novel causative element of IUGR.
Collapse
Affiliation(s)
- Nadia Alfaidy
- Commissariat à l'Energie Atomique (CEA), DSV-iRTSV, Grenoble, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Vittet D, Merdzhanova G, Prandini MH, Feige JJ, Bailly S. TGFβ1 inhibits lymphatic endothelial cell differentiation from mouse embryonic stem cells. J Cell Physiol 2012; 227:3593-602. [PMID: 22287283 DOI: 10.1002/jcp.24063] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The lymphatic vasculature is essential for the maintenance of tissue fluid, immune surveillance, and dissemination of metastasis. Recently, several models for lymphatic vascular research and markers specific for lymphatic endothelium have been characterized. Despite these significant achievements, our understanding of the early lymphatic development is still rather limited. The purpose of the study was to further define early lymphatic differentiation regulatory pathways. In the present study, we have developed conditions leading to lymphatic endothelial cell differentiation under both serum-rich and serum-free conditions, using the coculture system of Flk-1-positive vascular precursors derived from murine embryonic stem (ES) cells grown on an OP9 stromal cell layer. In this work, we also identified Transforming Growth Factor-β1 (TGFβ1) as a negative regulator of lymphvasculogenesis from ES-derived vascular progenitors. Finally, we could show that TGFβ1 addition decreases COUP-TFII and Sox18 mRNA levels, which are two transcription factors known to be involved in early lymphatic endothelial differentiation. Taken together these findings support the concept that manipulating the TGFβ signaling pathway may represent an interesting target to favor lymphatic endothelial cell expansion for cell replacement strategies.
Collapse
|
31
|
Brouillet S, Hoffmann P, Feige JJ, Alfaidy N. EG-VEGF: a key endocrine factor in placental development. Trends Endocrinol Metab 2012; 23:501-8. [PMID: 22709436 DOI: 10.1016/j.tem.2012.05.006] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Revised: 05/14/2012] [Accepted: 05/21/2012] [Indexed: 10/28/2022]
Abstract
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF), also named prokineticin 1, is the canonical member of the prokineticin family. Numerous reports suggest a direct involvement of this peptide in normal and pathological reproductive processes. Recent advances propose EG-VEGF as a key endocrine factor that controls many aspects of placental development and suggest its involvement in the development of preeclampsia (PE), the most threatening pathology of human pregnancy. This review describes the finely tuned action and regulation of EG-VEGF throughout human pregnancy, argues for its clinical relevance as a potential diagnostic marker of the onset of PE, and discusses future research directions for therapeutic targeting of EG-VEGF.
Collapse
Affiliation(s)
- Sophie Brouillet
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Grenoble, France
| | | | | | | |
Collapse
|
32
|
Ciais D, Cherradi N, Feige JJ. Multiple functions of tristetraprolin/TIS11 RNA-binding proteins in the regulation of mRNA biogenesis and degradation. Cell Mol Life Sci 2012; 70:2031-44. [PMID: 22968342 DOI: 10.1007/s00018-012-1150-y] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2012] [Revised: 08/27/2012] [Accepted: 08/28/2012] [Indexed: 02/06/2023]
Abstract
Members of the tristetraprolin (TTP/TIS11) family are important RNA-binding proteins initially characterized as mediators of mRNA degradation. They act via their interaction with AU-rich elements present in the 3'UTR of regulated transcripts. However, it is progressively appearing that the different steps of mRNA processing and fate including transcription, splicing, polyadenylation, translation, and degradation are coordinately regulated by multifunctional integrator proteins that possess a larger panel of functions than originally anticipated. Tristetraprolin and related proteins are very good examples of such integrators. This review gathers the present knowledge on the functions of this family of RNA-binding proteins, including their role in AU-rich element-mediated mRNA decay and focuses on recent advances that support the concept of their broader involvement in distinct steps of mRNA biogenesis and degradation.
Collapse
Affiliation(s)
- Delphine Ciais
- Institut National de la Santé et de la Recherche Médicale (INSERM) U1036, 17 rue des Martyrs, 38054, Grenoble Cedex 9, France
| | | | | |
Collapse
|
33
|
Feige JJ, Quirin N, Souchelnitskiy S. TGFß, un peptide biologique sous contrôle : formes latentes et mécanismes d'activation. ACTA ACUST UNITED AC 2012. [DOI: 10.4267/10608/850] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
de Oliveira FL, Araújo-Jorge TC, de Souza EM, de Oliveira GM, Degrave WM, Feige JJ, Bailly S, Waghabi MC. Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease. PLoS Negl Trop Dis 2012; 6:e1696. [PMID: 22720109 PMCID: PMC3373641 DOI: 10.1371/journal.pntd.0001696] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2011] [Accepted: 03/19/2012] [Indexed: 01/02/2023] Open
Abstract
Background Chagas disease induced by Trypanosoma cruzi (T. cruzi) infection is a major cause of mortality and morbidity affecting the cardiovascular system for which presently available therapies are largely inadequate. Transforming Growth Factor beta (TGFß) has been involved in several regulatory steps of T. cruzi invasion and in host tissue fibrosis. GW788388 is a new TGFß type I and type II receptor kinase inhibitor that can be orally administered. In the present work, we studied its effects in vivo during the acute phase of experimental Chagas disease. Methodology/Principal Findings Male Swiss mice were infected intraperitoneally with 104 trypomastigotes of T. cruzi (Y strain) and evaluated clinically. We found that this compound given once 3 days post infection (dpi) significantly decreased parasitemia, increased survival, improved cardiac electrical conduction as measured by PR interval in electrocardiography, and restored connexin43 expression. We could further show that cardiac fibrosis development, evaluated by collagen type I and fibronectin expression, could be inhibited by this compound. Interestingly, we further demonstrated that administration of GW788388 at the end of the acute phase (20 dpi) still significantly increased survival and decreased cardiac fibrosis (evaluated by Masson's trichrome staining and collagen type I expression), in a stage when parasite growth is no more central to this event. Conclusion/Significance This work confirms that inhibition of TGFß signaling pathway can be considered as a potential alternative strategy for the treatment of the symptomatic cardiomyopathy found in the acute and chronic phases of Chagas disease. Cardiac damage and dysfunction are prominent features in patients with chronic Chagas disease, which is caused by infection with the protozoan parasite Trypanosoma cruzi (T. cruzi) and affects 10–12 million individuals in South and Central America. Our group previously reported that transforming growth factor beta (TGFß) is implicated in several regulatory aspects of T. cruzi invasion and growth and in host tissue fibrosis. In the present work, we evaluated the therapeutic action of an oral inhibitor of TGFß signaling (GW788388) administered during the acute phase of experimental Chagas disease. GW788388 treatment significantly reduced mortality and decreased parasitemia. Electrocardiography showed that GW788388 treatment was effective in protecting the cardiac conduction system, preserving gap junction plaque distribution and avoiding the development of cardiac fibrosis. Inhibition of TGFß signaling in vivo appears to potently decrease T. cruzi infection and to prevent heart damage in a preclinical mouse model. This suggests that this class of molecules may represent a new therapeutic tool for acute and chronic Chagas disease that warrants further pre-clinical exploration. Administration of TGFß inhibitors during chronic infection in mouse models should be further evaluated, and future clinical trials should be envisaged.
Collapse
Affiliation(s)
- Fabiane L. de Oliveira
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
- Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Tania C. Araújo-Jorge
- Laboratório de Inovações em Terapias, Ensino e Bioprodutos, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Elen M. de Souza
- Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Gabriel M. de Oliveira
- Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Wim M. Degrave
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| | - Jean-Jacques Feige
- INSERM, Unité 1036, Biology of Cancer and Infection, Grenoble, France
- UJF-Grenoble 1, Biology of Cancer and Infection, Grenoble, France
- CEA, DSV/iRTSV, Biology of Cancer and Infection, Grenoble, France
| | - Sabine Bailly
- INSERM, Unité 1036, Biology of Cancer and Infection, Grenoble, France
- UJF-Grenoble 1, Biology of Cancer and Infection, Grenoble, France
- CEA, DSV/iRTSV, Biology of Cancer and Infection, Grenoble, France
- * E-mail:
| | - Mariana C. Waghabi
- Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
| |
Collapse
|
35
|
Herbet M, Salomon A, Feige JJ, Thomas M. Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. PLoS Genet 2012; 8:e1002700. [PMID: 22589739 PMCID: PMC3349738 DOI: 10.1371/journal.pgen.1002700] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2011] [Accepted: 03/26/2012] [Indexed: 11/25/2022] Open
Abstract
Sporadic adrenocortical carcinomas (ACC) are rare endocrine neoplasms with a dismal prognosis. By contrast, benign tumors of the adrenal cortex are common in the general population. Whether benign tumors represent a separate entity or are in fact part of a process of tumor progression ultimately leading to an ACC is still an unresolved issue. To this end, we have developed a mouse model of tumor progression by successively transducing genes altered in adrenocortical tumors into normal adrenocortical cells. The introduction in different orders of the oncogenic allele of Ras (H-RasG12V) and the mutant p53DD that disrupts the p53 pathway yielded tumors displaying major differences in histological features, tumorigenicity, and metastatic behavior. Whereas the successive expression of RasG12V and p53DD led to highly malignant tumors with metastatic behavior, reminiscent of those formed after the simultaneous introduction of p53DD and RasG12V, the reverse sequence gave rise only to benign tumors. Microarray profiling revealed that 157 genes related to cancer development and progression were differentially expressed. Of these genes, 40 were up-regulated and 117 were down-regulated in malignant cell populations as compared with benign cell populations. This is the first evidence-based observation that ACC development follows a multistage progression and that the tumor phenotype is directly influenced by the order of acquisition of genetic alterations. A sequential acquisition of genetic events is critical in tumorigenesis, and a dysregulation of a limited set of pathways has been demonstrated as sufficient to progressively transform normal cells into tumor cells in several human tissues. However, in the case of adrenocortical tumorigenesis, whether benign tumors represent a separate entity or are in fact part of a process of tumor progression leading ultimately to an adrenal carcinoma is still an unresolved issue. Moreover, the importance of the order in which these genetic events must occur to transform a cell has not been established. Here, we developed a tissue reconstruction model in mice that allows direct comparison of cells modified with sequential introduction of two genetic events. This revealed that adrenocortical tumor development follows a multistage progression and that the tumor phenotype, including histopathology and metastatic behavior, is directly influenced by the order of acquisition of genetic alterations.
Collapse
Affiliation(s)
- Maryline Herbet
- Institut National de la Santé et de la Recherche, Unité 1036, Grenoble, France
- Commissariat à l'Énergie Atomique, Institut de Recherches en Technologies et Sciences pour le Vivant, Biologie du Cancer et de l'Infection, Grenoble, France
- Université Joseph Fourier-Grenoble I, Grenoble, France
| | - Aude Salomon
- Institut National de la Santé et de la Recherche, Unité 1036, Grenoble, France
- Commissariat à l'Énergie Atomique, Institut de Recherches en Technologies et Sciences pour le Vivant, Biologie du Cancer et de l'Infection, Grenoble, France
- Université Joseph Fourier-Grenoble I, Grenoble, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche, Unité 1036, Grenoble, France
- Commissariat à l'Énergie Atomique, Institut de Recherches en Technologies et Sciences pour le Vivant, Biologie du Cancer et de l'Infection, Grenoble, France
- Université Joseph Fourier-Grenoble I, Grenoble, France
| | - Michaël Thomas
- Institut National de la Santé et de la Recherche, Unité 1036, Grenoble, France
- Commissariat à l'Énergie Atomique, Institut de Recherches en Technologies et Sciences pour le Vivant, Biologie du Cancer et de l'Infection, Grenoble, France
- Université Joseph Fourier-Grenoble I, Grenoble, France
- * E-mail:
| |
Collapse
|
36
|
Singh P, Soon PSH, Feige JJ, Chabre O, Zhao JT, Cherradi N, Lalli E, Sidhu SB. Dysregulation of microRNAs in adrenocortical tumors. Mol Cell Endocrinol 2012; 351:118-28. [PMID: 21996374 DOI: 10.1016/j.mce.2011.09.041] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2011] [Revised: 09/22/2011] [Accepted: 09/27/2011] [Indexed: 01/22/2023]
Abstract
MicroRNAs (miRNAs) are short non-coding RNAs that are involved in the epigenetic regulation of cellular processes. Different malignancies are often associated with the deregulation of specific sets of miRNAs. The prognosis of adrenocortical cancers (ACCs) is very poor as compared to adrenocortical adenomas (ACAs), and even within ACCs there are cases with better disease specific survival. An improved understanding of the pathobiology of this disease will therefore be useful in facilitating better management of ACCs as well as distinguishing high risk versus low risk subgroups. One third of coding genes are regulated by miRNAs and therefore changes in miRNA expression may be associated with cancer development and progression. In this review we summarize the current understanding of miRNAs in adrenocortical tumors, and highlight their potential in differentiating between ACCs and ACAs, risk stratification and prognosis.
Collapse
Affiliation(s)
- Puneet Singh
- Cancer Genetics Unit, Hormones & Cancer Group, Kolling Institute of Medical Research, University of Sydney, Sydney, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Bidart M, Ricard N, Levet S, Samson M, Mallet C, David L, Subileau M, Tillet E, Feige JJ, Bailly S. BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol Life Sci 2012; 69:313-24. [PMID: 21710321 DOI: 10.1007/s00018-011-0751-1] [Citation(s) in RCA: 125] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Revised: 05/31/2011] [Accepted: 06/07/2011] [Indexed: 01/29/2023]
Abstract
Bone Morphogenetic Protein 9 (BMP9) has been recently found to be the physiological ligand for the activin receptor-like kinase 1 (ALK1), and to be a major circulating vascular quiescence factor. Moreover, a soluble chimeric ALK1 protein (ALK1-Fc) has recently been developed and showed powerful anti-tumor growth and anti-angiogenic effects. However, not much is known concerning BMP9. This prompted us to investigate the human endogenous sources of this cytokine and to further characterize its circulating form(s) and its function. Analysis of BMP9 expression reveals that BMP9 is produced by hepatocytes and intrahepatic biliary epithelial cells. Gel filtration analysis combined with ELISA and biological assays demonstrate that BMP9 circulates in plasma (1) as an unprocessed inactive form that can be further activated by furin a serine endoprotease, and (2) as a mature and fully active form (composed of the mature form associated with its prodomain). Analysis of BMP9 circulating levels during mouse development demonstrates that BMP9 peaks during the first 3 weeks after birth and then decreases to 2 ng/mL in adulthood. We also show that circulating BMP9 physiologically induces a constitutive Smad1/5/8 phosphorylation in endothelial cells. Taken together, our results argue for the role of BMP9 as a hepatocyte-derived factor, circulating in inactive (40%) and active (60%) forms, the latter constantly activating endothelial cells to maintain them in a resting state.
Collapse
Affiliation(s)
- Marie Bidart
- Biology of Cancer and Infection, INSERM, Grenoble, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Brouillet S, Hoffmann P, Chauvet S, Salomon A, Chamboredon S, Sergent F, Benharouga M, Feige JJ, Alfaidy N. Revisiting the role of hCG: new regulation of the angiogenic factor EG-VEGF and its receptors. Cell Mol Life Sci 2011; 69:1537-50. [PMID: 22138749 DOI: 10.1007/s00018-011-0889-x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Revised: 11/02/2011] [Accepted: 11/14/2011] [Indexed: 11/25/2022]
Abstract
Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor reported to be specific for endocrine tissues, including the placenta. Its biological activity is mediated via two G protein-coupled receptors, prokineticin receptor 1 (PROKR1) and prokineticin receptor 2 (PROKR2). We have recently shown that (i) EG-VEGF expression peaks between the 8th and 11th weeks of gestation, (ii) its mRNA and protein levels are up-regulated by hypoxia, (iii) EG-VEGF is a negative regulator of trophoblast invasion and (iv) its circulating levels are increased in preeclampsia (PE), the most threatening pathology of pregnancy. Here, we investigated the regulation of the expression of EG-VEGF and its receptors by hCG, a key pregnancy hormone that is also deregulated in PE. During the first trimester of pregnancy, hCG and EG-VEGF exhibit the same pattern of expression, suggesting that EG-VEGF is potentially regulated by hCG. Both placental explants (PEX) and primary cultures of trophoblasts from the first trimester of pregnancy were used to investigate this hypothesis. Our results show that (i) LHCGR, the hCG receptor, is expressed both in cyto- and syncytiotrophoblasts, (ii) hCG increases EG-VEGF, PROKR1 and PROKR2 mRNA and protein expression in a dose- and time-dependent manner, (iii) hCG increases the release of EG-VEGF from PEX conditioned media, (iv) hCG effects are transcriptional and post-transcriptional and (v) the hCG effects are mediated by cAMP via cAMP response elements present in the EG-VEGF promoter region. Altogether, these results demonstrate a new role for hCG in the regulation of EG-VEGF and its receptors, an emerging regulatory system in placental development.
Collapse
MESH Headings
- Base Sequence
- Cells, Cultured
- Chorionic Gonadotropin/metabolism
- Chorionic Gonadotropin/pharmacology
- DNA Primers/genetics
- Female
- Gene Expression/drug effects
- Humans
- In Vitro Techniques
- Models, Biological
- Molecular Sequence Data
- Placenta/drug effects
- Placenta/metabolism
- Placentation
- Pregnancy
- Pregnancy Trimester, First
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptors, G-Protein-Coupled/genetics
- Receptors, G-Protein-Coupled/metabolism
- Receptors, LH/metabolism
- Receptors, Peptide/genetics
- Receptors, Peptide/metabolism
- Trophoblasts/drug effects
- Trophoblasts/metabolism
- Vascular Endothelial Growth Factor, Endocrine-Gland-Derived/genetics
- Vascular Endothelial Growth Factor, Endocrine-Gland-Derived/metabolism
Collapse
Affiliation(s)
- S Brouillet
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Laboratoire Biologie du Cancer et de l'Infection, Grenoble, France
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
We report the characterization of Delta-like-4 (Dll4), an angiogenesis-related gene for which haploinsufficiency is lethal, as an additional target of Tis11b-mediated regulation. Unexpectedly, we show that Tis11b does not alter mRNA stability but rather seems to modulate 3′-processing of Dll4 mRNA in endothelial cells. Tis11b/BRF1 belongs to the tristetraprolin family, the members of which are involved in AU-rich-dependent regulation of mRNA stability/degradation. Mouse inactivation of the Tis11b gene has revealed disorganization of the vascular network and up-regulation of the proangiogenic factor VEGF. However, the VEGF deregulation alone cannot explain the phenotype of Tis11b knockouts. Therefore we investigated the role of Tis11b in expression of Dll4, another angiogenic gene for which haploinsufficiency is lethal. In this paper, we show that Tis11b silencing in endothelial cells leads to up-regulation of Dll4 protein and mRNA expressions, indicating that Dll4 is a physiological target of Tis11b. Tis11b protein binds to endogenous Dll4 mRNA, and represses mRNA expression without affecting its stability. In the Dll4 mRNA 3′ untranslated region, we identified one particular AUUUA motif embedded in a weak noncanonical polyadenylation (poly(A)) signal as the major Tis11b-binding site. Moreover, we observed that inhibition of Tis11b expression changes the ratio between mRNAs that are cleaved or read through at the poly(A) signal position, suggesting that Tis11b can interfere with mRNA cleavage and poly(A) efficiency. Last, we report that this Tis11b-mediated mechanism is used by endothelial cells under hypoxia for controlling Dll4 mRNA levels. This work constitutes the first description of a new function for Tis11b in mammalian cell mRNA 3′-end maturation.
Collapse
Affiliation(s)
- Agnès Desroches-Castan
- Institut National de la Santé et de la Recherche Médicale, Unité 1036, Biologie du Cancer et de l'Infection, Grenoble F-38054, France
| | | | | | | |
Collapse
|
40
|
Chamboredon S, Ciais D, Desroches-Castan A, Savi P, Bono F, Feige JJ, Cherradi N. Hypoxia-inducible factor-1α mRNA: a new target for destabilization by tristetraprolin in endothelial cells. Mol Biol Cell 2011; 22:3366-78. [PMID: 21775632 PMCID: PMC3172262 DOI: 10.1091/mbc.e10-07-0617] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Endothelial cells (ECs) are the primary sensors of variations in blood oxygen concentrations. They use the hypoxia-sensitive stabilization of the hypoxia-inducible factor-1α (HIF-1α) transcription factor to engage specific transcriptional programs in response to oxygen changes. The regulation of HIF-1α expression is well documented at the protein level, but much less is known about the control of its mRNA stability. Using small interfering RNA knockdown experiments, reporter gene analyses, ribonucleoprotein immunoprecipitations, and mRNA half-life determinations, we report a new regulatory mechanism of HIF-1α expression in ECs. We demonstrate that 1) sustained hypoxia progressively decreases HIF-1α mRNA while HIF-1α protein levels rapidly peak after 3 h and then slowly decay; 2) silencing the mRNA-destabilizing protein tristetraprolin (TTP) in ECs reverses hypoxia-induced down-regulation of HIF-1α mRNA; 3) the decrease in the half-life of Luciferase-HIF-1α-3'UTR reporter transcript that is observed after prolonged hypoxia is mediated by TTP; 4) TTP binds specifically to HIF-1α 3'UTR; and 5) the most distal AU-rich elements present in HIF-1α 3'UTR (composed of two hexamers) are sufficient for TTP-mediated repression. Finally, we bring evidence that silencing TTP expression enhances hypoxia-induced increase in HIF-1α protein levels with a concomitant increase in the levels of the carbonic anhydrase enzyme CA IX, thus suggesting that TTP physiologically controls the expression of a panel of HIF-1α target genes. Altogether, these data reveal a new role for TTP in the control of gene expression during the response of endothelial cell to hypoxia.
Collapse
Affiliation(s)
- Sandrine Chamboredon
- Institut National de la Santé et de la Recherche Médicale, Unité 1036 Grenoble, France
| | | | | | | | | | | | | |
Collapse
|
41
|
Assie G, Louiset E, Sturm N, René-Corail F, Groussin L, Bertherat J, Thomas M, Lefebvre H, Feige JJ, Clauser E, Chabre O, Cherradi N. Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome. J Clin Endocrinol Metab 2010; 95:E253-62. [PMID: 20660048 DOI: 10.1210/jc.2009-2281] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
CONTEXT Stimulation of cortisol secretion through abnormally expressed G protein-coupled receptors (GPCRs) is a frequent feature of ACTH-independent macronodular adrenal hyperplasia (AIMAH). This has opened a pharmacological strategy that targets GPCRs for the treatment of Cushing's syndrome in AIMAH. However, only few drugs are available for the presently described GPCRs. OBJECTIVE The objective of the study was to identify new GPCR targets for the pharmacological treatment of adrenal Cushing's syndrome. DESIGN AND PATIENTS We designed a cDNA chip containing 865 nucleotidic sequences of GPCRs. mRNAs were extracted from three normal adrenals, 18 AIMAHs, four adrenals from Cushing's disease patients, and 13 cortisol-secreting adenomas. A set of GPCR mRNAs that showed significantly higher or lower expression in AIMAH than in normal adrenal were studied by quantitative RT-PCR analysis. Analysis of protein expression and function were performed on selected GPCRs. SETTING The study was conducted at a tertiary care center and basic research laboratories. RESULTS The ACTH MC2 receptor showed a low expression in 15 of 18 AIMAHs samples, whereas several previously undescribed GPCR genes were found highly expressed in a subset of AIMAH, such as the receptors for motilin (MLNR; three of 18 AIMAHs) and γ-aminobutyric acid (GABBR1; five of 18 AIMAHs), and the α2A adrenergic receptor (ADRA2A; 13 of 18 AIMAHs), on which we focused our attention. Western blot and immunochemistry analyses showed expression of ADRA2A protein in AIMAH but not in normal adrenal cortex. The ADRA2A agonist clonidine enhanced both basal and stimulated cortisol production. Clonidine-induced increase in basal cortisol levels was blocked by the ADRA2A antagonist yohimbine. CONCLUSION ADRA2A is a potential target for pharmacological treatment of Cushing's syndrome linked to AIMAH.
Collapse
Affiliation(s)
- Guillaume Assie
- Université Paris Descartes, Institut National de la Santé et de la Recherche Médicale Unité 567, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
Adiponectin is an adipokine with insulin-sensitizing, anti-inflammatory, anti-atherogenic, and anti-proliferative effects. The expression of specific adiponectin receptors in the placenta and in the endometrium suggests a role for this cytokine in placental development, but this role has not yet been elucidated. The invasion of trophoblast cells during the first trimester of pregnancy being crucial to placentation process, we have studied adiponectin effects on human trophoblast invasive capacities. We found that adiponectin stimulated human trophoblast cell migration in HTR-8/SVneo cells in a dose-independent manner. In addition, adiponectin also significantly enhanced invasion of HTR-8/SVneo cells and of human extravillous trophoblast from first trimester placenta. These pro-invasive effects of adiponectin in human trophoblasts seem to be mediated in part via increased matrix metalloproteinases (MMP2 and MMP9) activities and via repression of TIMP2 mRNA expression. Our results suggest that adiponectin could be a positive regulator of the early invasion process by modulating the MMP/TIMP balance. Moreover, these results provide an insight into the role of adiponectin in pathological conditions characterized by insufficient or excessive trophoblast invasion.
Collapse
Affiliation(s)
- Delphine Benaitreau
- Service de Biochimie et Biologie Moléculaire, UPRES-EA 2493, Faculté de Médecine Paris-Ile de France Ouest, PRES Universud Paris, Centre Hospitalier de Poissy-Saint Germain, Université de Versailles-St-Quentin, Poissy, France
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Assie G, Louiset E, Sturm N, Rénée-Corail F, Groussin L, Bertherat J, Thomas M, Lefebvre H, Feige JJ, Clauser E, Chabre O, Cherradi N. Systematic Analysis of G Protein-Coupled Receptor Gene Expression in Adrenocorticotropin-Independent Macronodular Adrenocortical Hyperplasia Identifies Novel Targets for Pharmacological Control of Adrenal Cushing’s Syndrome. Mol Endocrinol 2010. [DOI: 10.1210/mend.24.8.9995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
44
|
Hoffmann P, Saoudi Y, Benharouga M, Graham CH, Schaal JP, Mazouni C, Feige JJ, Alfaidy N. Role of EG-VEGF in human placentation: Physiological and pathological implications. J Cell Mol Med 2010; 13:2224-2235. [PMID: 19602057 DOI: 10.1111/j.1582-4934.2008.00554.x] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Pre-eclampsia (PE), the major cause of maternal morbidity and mortality, is thought to be caused by shallow invasion of the maternal decidua by extravillous trophoblasts (EVT). Data suggest that a fine balance between the expressions of pro- and anti-invasive factors might regulate EVT invasiveness. Recently, we showed that the expression of the new growth factor endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is high in early pregnancy but falls after 11 weeks, suggesting an essential role for this factor in early pregnancy. Using human villous explants and HTR-8/SVneo, a first trimester extravillous trophoblast cell line, we showed differential expression of EG-VEGF receptors, PKR1 and PKR2, in the placenta and demonstrated that EG-VEGF inhibits EVT migration, invasion and tube-like organisation. EG-VEGF inhibitory effect on invasion was supported by a decrease in matrix metalloproteinase (MMP)-2 and MMP-9 production. Interference with PKR2 expression, using specific siRNAs, reversed the EG-VEGF-induced inhibitory effects. Furthermore, we determined EG-VEGF circulating levels in normal and PE patients. Our results showed that EG-VEGF levels were highest during the first trimester of pregnancy and decreased thereafter to non-pregnant levels. More important, EG-VEGF levels were significantly elevated in PE patients compared with age-matched controls. These findings identify EG-VEGF as a novel paracrine regulator of trophoblast invasion. We speculate that a failure to correctly down-regulate placental expression of EG-VEGF at the end of the first trimester of pregnancy might lead to PE.
Collapse
Affiliation(s)
- Pascale Hoffmann
- Institut National de la Santé et de la Recherche Médicale, Grenoble, France.,Commissariat à l'Energie Atomique, iRTSV, Grenoble, France.,Université Joseph Fourier, Grenoble, France.,Centre Hospitalier Régional Universitaire de Grenoble, Département de Gynécologie, Obstétrique et Médecine de la Reproduction, Grenoble, France
| | - Yasmina Saoudi
- Commissariat à l'Energie Atomique, iRTSV, Grenoble, France.,Université Joseph Fourier, Grenoble, France.,Institut National de la Santé et de la Recherche Médicale, Grenoble, France
| | - Mohamed Benharouga
- Commissariat à l'Energie Atomique, iRTSV, Grenoble, France.,Université Joseph Fourier, Grenoble, France.,Centre National de la Recherche Scientifique, Grenoble, France
| | - Charles H Graham
- Department of Anatomy and Cell Biology, Queen's University, Kingston, Ontario, Canada
| | - Jean-Patrick Schaal
- Commissariat à l'Energie Atomique, iRTSV, Grenoble, France.,Université Joseph Fourier, Grenoble, France
| | - Chafika Mazouni
- Département de Gynécologie, Obstétrique, Hôpital de la Conception, Marseille, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale, Grenoble, France.,Commissariat à l'Energie Atomique, iRTSV, Grenoble, France.,Université Joseph Fourier, Grenoble, France
| | - Nadia Alfaidy
- Institut National de la Santé et de la Recherche Médicale, Grenoble, France.,Commissariat à l'Energie Atomique, iRTSV, Grenoble, France.,Université Joseph Fourier, Grenoble, France
| |
Collapse
|
45
|
Brouillet S, Hoffmann P, Benharouga M, Salomon A, Schaal JP, Feige JJ, Alfaidy N. Molecular characterization of EG-VEGF-mediated angiogenesis: differential effects on microvascular and macrovascular endothelial cells. Mol Biol Cell 2010; 21:2832-43. [PMID: 20587779 PMCID: PMC2921113 DOI: 10.1091/mbc.e10-01-0059] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Endocrine gland derived vascular endothelial growth factor (EG-VEGF) also called prokineticin (PK1), has been identified and linked to several biological processes including angiogenesis. EG-VEGF is abundantly expressed in the highest vascularized organ, the human placenta. Here we characterized its angiogenic effect using different experimental procedures. Immunohistochemistry was used to localize EG-VEGF receptors (PROKR1 and PROKR2) in placental and umbilical cord tissue. Primary microvascular placental endothelial cell (HPEC) and umbilical vein-derived macrovascular EC (HUVEC) were used to assess its effects on proliferation, migration, cell survival, pseudovascular organization, spheroid sprouting, permeability and paracellular transport. siRNA and neutralizing antibody strategies were used to differentiate PROKR1- from PROKR2-mediated effects. Our results show that 1) HPEC and HUVEC express both types of receptors 2) EG-VEGF stimulates HPEC's proliferation, migration and survival, but increases only survival in HUVECs. and 3) EG-VEGF was more potent than VEGF in stimulating HPEC sprout formation, pseudovascular organization, and it significantly increases HPEC permeability and paracellular transport. More importantly, we demonstrated that PROKR1 mediates EG-VEGF angiogenic effects, whereas PROKR2 mediates cellular permeability. Altogether, these data characterized angiogenic processes mediated by EG-VEGF, depicted a new angiogenic factor in the placenta, and suggest a novel view of the regulation of angiogenesis in placental pathologies.
Collapse
Affiliation(s)
- Sophie Brouillet
- Institut National de la Santé et de la Recherche Médicale, Unité 878, Grenoble, France
| | | | | | | | | | | | | |
Collapse
|
46
|
Marie B, Bailly S, Feige JJ, Mallet C, Ricard N. 62: Caractérisation d’un nouveau marqueur circulant de l’angiogenèse tumorale: BMP9 le ligand du récepteur endothélial ALK1. Bull Cancer 2010. [DOI: 10.1016/s0007-4551(15)31155-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Waghabi MC, Coutinho-Silva R, Feige JJ, Higuchi MDL, Becker D, Burnstock G, Araújo-Jorge TCD. Gap junction reduction in cardiomyocytes following transforming growth factor-β treatment and Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 2009; 104:1083-90. [DOI: 10.1590/s0074-02762009000800004] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2009] [Accepted: 10/19/2009] [Indexed: 11/21/2022] Open
Affiliation(s)
- Mariana C Waghabi
- Instituto Oswaldo Cruz-Fiocruz, Brasil; University College Medical School, UK
| | - Robson Coutinho-Silva
- University College Medical School, UK; Universidade Federal do Rio de Janeiro, Brasil
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale; Institut de Recherches en Technologies et Sciences pour le Vivant, France
| | | | | | | | | |
Collapse
|
48
|
Abstract
Bone morphogenetic proteins (BMPs) are multifunctional growth factors belonging to the transforming growth factor beta (TGFbeta) superfamily. Recent observations clearly emphasize the emerging role of BMPs in angiogenesis: (i) two genetic vascular diseases (hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH)) are caused by mutations in genes encoding components of the BMP signalling pathway (endoglin, ALK1 and BMPRII). (ii) BMP9 has been identified as the physiological ligand of the endothelial receptor ALK1 in association with BMPRII. This review will focus on the diverse functions of BMPs in angiogenesis. We will propose a model that distinguishes the BMP2, BMP7 and GDF5 subgroups from the BMP9 subgroup on the basis of their functional implication in the two phases of angiogenesis (activation and maturation).
Collapse
Affiliation(s)
- Laurent David
- Institut National de la Santé et de la Recherche Médicale, U878, 17 rue des Martyrs, 38054 Grenoble, France
| | | | | |
Collapse
|
49
|
Herbet M, Feige JJ, Thomas M. Insights into the role of genetic alterations in adrenocortical tumorigenesis. Mol Cell Endocrinol 2009; 300:169-74. [PMID: 19007854 DOI: 10.1016/j.mce.2008.10.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2008] [Revised: 10/09/2008] [Accepted: 10/10/2008] [Indexed: 02/08/2023]
Abstract
Whereas benign adrenocortical tumors are frequent in the population, adrenocortical carcinoma (ACC) is a rare cancer. Significant advances in the understanding of the pathogenesis of sporadic ACCs have been possible through the study of hereditary syndromes responsible for ACCs. The genetic alterations involved in these syndromes have also been found in sporadic ACCs. Several specific genes have been shown to be altered in sporadic ACCs. Despite these progresses, the underlying sequence(s) of events remains to be elucidated. Progressive transformation of a normal tissue into a benign tumor and ultimately into a carcinoma occurs via accumulation of genetic and epigenetic alterations. Likewise, a multistage model has been proposed for the adrenal tumor development. This review summarizes the molecular alterations likely involved in the multistage tumorigenesis and describes a mouse model which allows us to evaluate the effect of individual genes or combination of genes in the development of adrenocortical tumors.
Collapse
Affiliation(s)
- M Herbet
- Institut National de la Santé et de la Recherche Médicale, Unité 878, iRTSV-LAPV, CEA-G, 17 rue des Martyrs, 38054 Grenoble, Cedex 09, France
| | | | | |
Collapse
|
50
|
Duan H, Cherradi N, Feige JJ, Jefcoate C. cAMP-dependent posttranscriptional regulation of steroidogenic acute regulatory (STAR) protein by the zinc finger protein ZFP36L1/TIS11b. Mol Endocrinol 2009; 23:497-509. [PMID: 19179481 DOI: 10.1210/me.2008-0296] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Star is expressed in steroidogenic cells as 3.5- and 1.6-kb transcripts that differ only in their 3'-untranslated regions (3'-UTR). In mouse MA10 testis and Y-1 adrenal lines, Br-cAMP preferentially stimulates 3.5-kb mRNA. ACTH is similarly selective in primary bovine adrenocortical cells. The 3.5-kb form harbors AU-rich elements (AURE) in the extended 3'-UTR, which enhance turnover. After peak stimulation of 3.5-kb mRNA, degradation is seen. Star mRNA turnover is enhanced by the zinc finger protein ZFP36L1/TIS11b, which binds to UAUUUAUU repeats in the extended 3'-UTR. TIS11b is rapidly stimulated in each cell type in parallel with Star mRNA. Cotransfection of TIS11b selectively decreases cytomegalovirus-promoted Star mRNA and luciferase-Star 3'-UTR reporters harboring the extended 3'-UTR. Direct complex formation was demonstrated between TIS11b and the extended 3'-UTR of the 3.5-kb Star. AURE mutations revealed that TIS11b-mediated destabilization required the first two UAUUUAUU motifs. HuR, which also binds AURE, did not affect Star expression. Targeted small interfering RNA knockdown of TIS11b specifically enhanced stimulation of 3.5-kb Star mRNA in bovine adrenocortical cells, MA-10, and Y-1 cells but did not affect the reversals seen after peak stimulation. Direct transfection of Star mRNA demonstrated that Br-cAMP stimulated a selective turnover of 3.5-kb mRNA independent of AURE, which may correspond to these reversal processes. Steroidogenic acute regulatory (STAR) protein induction was halved by TIS11b knockdown, concomitant with decreased cholesterol metabolism. TIS11b suppression of 3.5-kb mRNA is therefore surprisingly coupled to enhanced Star translation leading to increased cholesterol metabolism.
Collapse
Affiliation(s)
- Haichuan Duan
- Department of Pharmacology, University of Wisconsin Medical School, Madison, Wisconsin 53706, USA
| | | | | | | |
Collapse
|